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Guidelines summarize and evaluate all available evidence, at the time
of the writing process, on a particular issue with the aim of assisting
health professionals in selecting the best management strategies for
an individual patient with a given condition, taking into account the
impact on outcome, as well as the risk–benefit ratio of particular
diagnostic or therapeutic means. Guidelines and recommendations
should help health professionals to make decisions in their daily prac-
tice; however, the final decisions concerning an individual patient
must be made by the responsible health professional(s), in consult-
ation with the patient and caregiver as appropriate.
A great number of guidelineshave been issued in recent years by the
European Society of Cardiology (ESC) and the European Society of
Anaesthesiology (ESA), as well as by other societies and organisations.
Because of their impact on clinical practice, quality criteria for the de-
velopment of guidelines have been established in order to make
all decisions transparent to the user. The recommendations for for-
mulating and issuing ESC/ESA Guidelines can be found on the ESC
web site (http://www.escardio.org/guidelines-surveys/esc-guidelines/
about/Pages/rules-writing.aspx). These ESC/ESA guidelines represent
the official position of these two societies on this given topic and are
regularly updated.
Members of this Task Force were selected by the ESC and ESA to
represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for management
(including diagnosis, treatment, prevention and rehabilitation) of a
given condition, according to the ESC Committee for Practice
Guidelines (CPG) and ESA Guidelines Committee policy. A critical
evaluation of diagnostic and therapeutic procedures was per-
formed, including assessment of the risk–benefit ratio. Estimates
of expected health outcomes for larger populations were included,
where data exist. The level of evidence and the strength of
recommendation of particular management options were
weighed and graded according to pre-defined scales, as outlined
in Tables 1 and 2.
The experts of thewriting and reviewingpanels completed ’declara-
tions of interest’ forms which might be perceived as real or potential
sources of conflicts of interest. These forms were compiled into one
file and can be found on the ESC web site (http://www.escardio.org/
guidelines). Any changes in declarations of interest that arise during
the writing period must be notified to the ESC/ESA and updated.
The Task Force received its entire financial support from the ESC
and ESA, without any involvement from the healthcare industry.
The ESC CPG supervises and co-ordinates the preparation of new
guidelines produced by Task Forces, expert groups or consensus
panels. The Committee is also responsible for the endorsement
process of these guidelines. The ESC and Joint Guidelines undergo
extensive review by the CPG and partner Guidelines Committee
and external experts. After appropriate revisions it is approved by
all the experts involved in the Task Force. The finalized document
is approved by the CPG/ESA for simultaneous publication in the
European Heart Journal and joint partner journal, in this instance
the European Journal of Anaesthesiology. It was developed after
careful consideration of the scientific and medical knowledge and
the evidence available at the time of their dating.
The task of developing ESC/ESA guidelines covers not only the
integration of the most recent research, but also the creation of edu-
cational tools and implementation programmes for the recommen-
dations. To implement the guidelines, condensed pocket versions,
summary slides, booklets with essential messages, summary cards
for non-specialists, electronic versions for digital applications
(smart phones etc.) are produced. These versions are abridged and
thus, if needed, one should always refer to the full-text version,
which is freely available on the ESC and ESA web sites. The national
societies of the ESC and of the ESA areencouraged to endorse, trans-
late and implement the ESC guidelines. Implementation programmes
Table 1 Classes of recommendations
Classes of 
recommendations
Suggested wording to use
Class I Evidence and/or general agreement 




divergence of opinion about the 
treatment or procedure. 
    Class IIa Weight of evidence/opinion is in Should be considered
    Class IIb
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective, and in some 
cases may be harmful. 
Is not recommended
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are needed because it has been shown that the outcome of disease
may be favourably influenced by the thorough application of clinical
recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC/ESA guide-
lines fully into account when exercising their clinical judgment, as
well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies; however, the ESC/ESA
guidelines do not, in any way whatsoever, override the individual re-
sponsibility of health professionals to make appropriate and accurate
decisions in consideration of the condition of each patient’s health
and in consultation with that patient and, where appropriate
and/or necessary, the patient’s caregiver. It is also the health profes-
sional’s responsibility to verify the rules and regulations applicable to
drugs and devices at the time of prescription.
2. Introduction
2.1 The magnitude of the problem
The present Guidelines focus on the cardiovascular management of
patients in whom heart disease is a potential source of complications
during non-cardiac surgery. The risk of perioperative complications
depends on the condition of the patient before surgery, the preva-
lence of comorbidities, and the urgency, magnitude, type, and dur-
ation of the surgical procedure.
More specifically, cardiac complications can arise in patients with
documented or asymptomatic ischaemic heart disease (IHD), left
ventricular (LV) dysfunction, valvular heart disease (VHD), and
arrhythmias, who undergo surgical procedures that are associated
with prolonged haemodynamic and cardiac stress. In the case of peri-
operative myocardial ischaemia, two mechanisms are important: (i) a
mismatch in the supply–demand ratio of blood flow, in response to
metabolic demand due to a coronary artery stenosis that may
become flow-limiting by perioperative haemodynamic fluctuations
and (ii) acute coronary syndromes (ACS) due to stress-induced
rupture of a vulnerable atherosclerotic plaque in combination with
vascular inflammation and altered vasomotion, as well as haemosta-
sis. LV dysfunction and arrhythmias may occur for various reasons at
all ages. Because the prevalence of not only IHD but also VHD and
arrhythmias increases with age, perioperative cardiac mortality and
morbidity are predominantly an issue in the adult population under-
going major non-cardiac surgery.
Themagnitudeof theproblem inEuropecanbestbeunderstood in
terms of (i) the size of the adult non-cardiac surgical group and (ii) the
average risk of cardiac complications in this cohort. Unfortunately,
systematic data on the annual number and type of operations—and
on patient outcomes—are only available at a national level in 23
European countries (41%).1 Additionally, data definitions vary, as
do data quantity and quality. A recent modelling strategy, based on
worldwide data available in 2004, estimated the number of major
operations to be at the rate of 4% of the world population per
year.1 When applied to Europe, with an overall population of over
500 million, this figure translates into a crude estimate of 19 million
major procedures annually. While the majority of these procedures
are performed in patients with minimal cardiovascular risk, 30% of
patients undergo extensive surgical procedures in the presence of
cardiovascular comorbidity; hence, 5.7 million procedures annually
are performed in European patients who present with increased
risk of cardiovascular complications.
Worldwide, non-cardiac surgery is associated with an average
overall complication rate of 7–11% and a mortality rate of 0.8–
1.5%, depending on safety precautions.2 Up to 42% of these are
caused by cardiac complications.3 When applied to the population
in the European Union member states, these figures translate into
at least 167 000 cardiac complications annually due to non-cardiac
surgical procedures, of which 19 000 are life-threatening.
2.2 Change in demographics
Within the next 20 years, the ageing of the population will have a
major impact on perioperative patient management. It is estimated
that elderly people require surgery four times as often than the
rest of the population.4 In Europe, it is estimated that the number
of patients undergoing surgery will increase by 25% by 2020. Over
the same time period, the elderly population will increase by 50%.
The total number of surgical procedures may increase even faster
because of the rising frequency of interventions with age.5 The
results of the United States National Hospital Discharge Survey
show that the number of surgical procedures will increase in
almost all age groups and that the largest increase will occur in the
middle-aged and elderly. Demographics of patients undergoing
surgery show a trend towards an increasing number of elderly
patients and comorbidities.6 Although mortality from cardiac
disease is decreasing in the general population, the prevalence of
IHD, heart failure, and cardiovascular risk factors—especially dia-
betes—is increasing. Among the significant comorbidities in elderly
patients presenting for general surgery, cardiovascular disease
(CVD) is the most prevalent.7 Age per se, however, seems to be re-
sponsible for only a small increase in the risk of complications;
greater risks are associated with urgency and significant cardiac, pul-
monary, and renal disease; thus, these conditions should have greater
impact on the evaluation of patient risk than age alone.
2.3 Purpose and organization
These Guidelines are intended for physicians and collaborators
involved in the pre-operative, operative, and post-operative care of
patients undergoing non-cardiac surgery.
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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The objective is to endorse a standardized and evidence-based ap-
proach to perioperative cardiac management. The Guidelines recom-
mend a practical, stepwise evaluation of the patient that integrates
clinical risk factors and test results with the estimated stress of the
planned surgical procedure. This results in an individualized cardiac
risk assessment, with the opportunity of initiating medical therapy, cor-
onary interventions, and specific surgical and anaesthetic techniques in
order to optimize the patient’s perioperative condition.
Compared with the non-surgical setting, data from randomized
clinical trials—which provide the ideal evidence-base for the guide-
lines—are sparse. Consequently, when no trials are available on a
specific cardiac-management regimen in the surgical setting, data
from the non-surgical setting are extrapolated and similar recom-
mendationsmade, butwith different levels of evidence. Anaesthesiol-
ogists, who are experts on the specific demands of the proposed
surgical procedure, will usually co-ordinate the pre-operative evalu-
ation. The majority of patients with stable heart disease can undergo
low and intermediate-risk surgery (Table 3) without additional evalu-
ation. Selected patients require evaluation by a team of integrated
multidisciplinary specialists including anaesthesiologists, cardiolo-
gists, and surgeons and, when appropriate, an extended team (e.g.
internists, intensivists, pulmonologists or geriatricians).8 Selected
patients include those identified by the anaesthesiologist because
of suspected or known cardiac disease with sufficient complexity
to carry a potential perioperative risk (e.g. congenital heart disease,
unstable symptoms or low functional capacity), patients in whom
pre-operative medical optimization is expected to reduce periopera-
tive risk before low- and intermediate-risk surgery, and patients with
known or high risk of cardiac disease who are undergoing high-risk
surgery. Guidelines have the potential to improve post-operative
outcomes and highlight the existence of a clear opportunity for im-
proving the quality of care in this high-risk group of patients. In add-
ition to promoting an improvement in immediate perioperative
care, guidelines should provide long-term advice.
Because of the availability of new evidence and the international
impact of the controversy over the DECREASE trials, the ESC/ESA
and American College of Cardiology/American Heart Association
both began the process of revising their respective guidelines concur-
rently. The respective writing committees independently performed
their literature review and analysis, and then developed their recom-
mendations. Once peer reviewof bothguidelineswascompleted, the
writing committees chose to discuss their respective recommenda-
tions regarding beta-blocker therapy and other relevant issues. Any
differences in recommendations were discussed and clearly articu-
lated in the text; however, the writing committees aligned a few
recommendations to avoid confusion within the clinical community,
except where international practice variation was prevalent.
Following the development and introduction of perioperative
cardiac guidelines, their effect on outcome should be monitored.
The objective evaluation of changes in outcome will form an essential
part of future perioperative guideline development.
Recommendations on pre-operative evaluation
Recommendations Classa Levelb Ref. c
Selected patients with cardiac 
disease undergoing low-and 
intermediate-risk non-cardiac 
surgery may be referred by 
the anaesthesiologist for  
cardiological evaluation and 
medical optimization.
IIb C
A multidisciplinary expert 
team should be considered for 
pre-operative evaluation of 
patients with known or high 







Table 3 Surgical risk estimate according to type of surgery or interventiona,b
CAS ¼ carotid artery stenting; CEA ¼ carotid endarterectomy.
aSurgical risk estimate is a broad approximation of 30-day risk of cardiovascular death and myocardial infarction that takes into account only the specific surgical intervention, without
considering the patient’s comorbidities.
bAdapted from Glance et al.11
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3.1 Surgical risk for cardiac events
Cardiac complications after non-cardiac surgery depend on
patient-related risk factors, on the type of surgery, and on the cir-
cumstances under which it takes place.9 Surgical factors that influ-
ence cardiac risk are related to the urgency, invasiveness, type,
and duration of the procedure, as well as the change in body core
temperature, blood loss, and fluid shifts.5 Every operation elicits a
stress response. This response is initiated by tissue injury and
mediated by neuro-endocrine factors, and may induce sympatho-
vagal imbalance. Fluid shifts in the perioperative period add to the
surgical stress. This stress increases myocardial oxygen demand.
Surgery also causes alterations in the balance between prothrom-
botic and fibrinolytic factors, potentially resulting in increased cor-
onary thrombogenicity. The extent of such changes is
proportionate to the extent and duration of the intervention.
These factors, together with patient position, temperature
management, bleeding, and type of anaesthesia, may contribute to
haemodynamic derangements, leading to myocardial ischaemia
and heart failure. General, locoregional, and neuraxial anaesthesia
differ in terms of the stress response evoked by surgery. Less
invasive anaesthetic techniques may reduce early mortality in
patients at intermediate-to-high cardiac risk and limit post-
operative complications.10 Although patient-specific factors are
more important than surgery-specific factors in predicting the
cardiac risk for non-cardiac surgical procedures, the type of
surgery cannot be ignored.9
With regard to cardiac risk, surgical interventions—which include
open or endovascular procedures—can be broadly divided into
low-risk, intermediate-risk, and high-risk groups, with estimated
30-day cardiac event rates (cardiac death and myocardial infarction)
of ,1%, 1–5%, and .5%, respectively (Table 3).
The need for, and value of, pre-operative cardiac evaluation will
also depend on the urgency of surgery. In the case of emergency sur-
gical procedures, such as those for ruptured abdominal aortic aneur-
ysm (AAA), major trauma, or for a perforated viscus, cardiac
evaluation will not alter the course or result of the intervention but
may influence management in the immediate perioperative period.
In non-emergency but urgent surgical conditions, such as bypass
for acute limb ischaemia or treatment of bowel obstruction, the mor-
bidity and mortality of the untreated underlying condition may out-
weigh the potential cardiac risk related to the intervention. In these
cases, cardiological evaluation may influence the perioperative mea-
sures taken to reduce cardiac risk but will not influence the decision
to perform the intervention. In some cases, the cardiac risk can also
influence the type of operation and guide the choice to less-invasive
interventions, such as peripheral arterial angioplasty instead of in-
fra-inguinal bypass, or extra-anatomical reconstruction instead of
an aortic procedure, even when these may yield less favourable
results in the long term. Finally, in some situations, the cardiac evalu-
ation (in as far as it can reliably predict perioperative cardiac compli-
cations and late survival) should be taken into consideration when
deciding whether to perform an intervention or manage conserva-
tively. This is the case in certain prophylactic interventions, such as
the treatment of small AAAs or asymptomatic carotid stenosis,
where the life expectancy of the patient and the risk of the oper-
ation are important factors in evaluating the potential benefit of the
surgical intervention.
3.2 Type of surgery
In general, endoscopic and endovascular techniques speed recovery,
decrease hospital stay, and reduce the rate of complications.12
However, randomized clinical trials comparing laparoscopic with
open techniques exclude older, sicker, and ’urgent’ patients, and
results from an expert-based randomized trial (laparoscopic vs.
open cholecystectomy) have shown no significant differences in
conversion rate, pain, complications, length of hospital stay, or
re-admissions.13
The wide variety of surgical procedures, in a myriad of different
contexts, makes difficult the assignation of a specific risk of a
major adverse cardiac event to each procedure. When alternative
methods to classical open surgery are considered, either through
endovascular or less-invasive endoscopic procedures, the
potential trade-offs between early benefits due to reduced
morbidity and mid- to long-term efficacy need to be taken into
account.
3.2.1 Endovascular vs. open vascular procedures
Vascular interventions are of specific interest, not only because they
carry the highest risk of cardiac complications, but also because of
the many studies that have shown that this risk can be influenced
by adequate perioperative measures in these patients.14 Open
aortic and infra-inguinal procedures must both be regarded as high-
risk procedures. Although it is a less-extensive intervention, infra-
inguinal revascularization entails a cardiac risk similar to—or even
higher than—that of aortic procedures. This can be explained
by the higher incidence of diabetes, renal dysfunction, IHD, and
advanced age in this patient group. This also explains why the risk
related to peripheral artery angioplasties, which are minimally inva-
sive procedures, is not negligible.
Endovascular AAA repair (EVAR) has been associated with
lower operative mortality and morbidity than open repair but this
advantage reduces with time, due to more frequent graft-related
complications and re-interventions in patients who underwent
EVAR, resulting in similar long-term AAA-related mortality and
total mortality.15–17
A meta-analysis of studies, comparing open surgical with
percutaneous transluminal methods for the treatment of femoro-
popliteal arterial disease, showed that bypass surgery is associated
with higher 30-day morbidity [odds ratio (OR) 2.93; 95%
confidence interval (CI) 1.34–6.41] and lower technical failure
than endovascular treatment, with no differences in 30-day mor-
tality; however, there were higher amputation-free and overall
survival rates in the bypass group at 4 years.18 Therefore, multiple
factors must be taken into consideration when deciding which
type of procedure serves the patient best. An endovascular-first ap-
proach may be advisable in patients with significant comorbidity,
whereas a bypass procedure may be offered as a first-line interven-
tional treatment for fit patients with a longer life expectancy.19
Carotid artery stenting has appeared as an attractive, less-invasive
alternative to CEA; however, although CAS reduces the rate of
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periprocedural myocardial infarction and cranial nerve palsy, the
combined 30-day rate of stroke or death is higher than CEA,
particularly in symptomatic and older patients, driven by a differ-
ence in the risk of periprocedural non-disabling stroke.20,21
The benefit of carotid revascularization is particularly high in
patients with recent (,3 months) transient ischaemic attack
(TIA) or stroke and a .60% carotid artery bifurcation stenosis.22
In neurologically asymptomatic patients, carotid revascularization
benefit is questionable, compared with modern medical
therapy, except in patients with a .80% carotid stenosis and an
estimated life expectancy of .5 years.21 The choice between
CEA and CAS must integrate operator experience and results,
anatomical characteristics of the arch vessels, neck features, and
comorbidities.21 – 23
3.2.2 Open vs. laparoscopic or thoracoscopic
procedures
Laparoscopic procedures, compared with open procedures, have
the advantage of causing less tissue trauma and intestinal paralysis,
resulting in less incisional pain, better post-operative pulmonary
function, significantly fewer wall complications, and diminished post-
operativefluid shifts related to bowel paralysis.24 However, the pneu-
moperitoneum required for these procedures results in elevated
intra-abdominal pressure and a reduction in venous return. Typical
physiological sequelae are secondary to increased intra-abdominal
pressure and absorption of the gaseous medium used for insufflation.
While healthy individuals on controlled ventilation typically tolerate
pneumoperitoneum, debilitated patients with cardiopulmonary
compromise and obese patients may experience adverse conse-
quences.25 Pneumoperitoneum and Trendelenburg position result
in increased mean arterial pressure, central venous pressure, mean
pulmonary artery, pulmonary capillary wedge pressure, and systemic
vascular resistance impairing cardiac function.26,27 Therefore, com-
pared with open surgery, cardiac risk in patients with heart failure
is not reduced in patients undergoing laparoscopy, and both should
be evaluated in the same way. This is especially true in patients under-
going interventions for morbid obesity, but also in other types of
surgery, considering the risk of conversion to an open proced-
ure.28,29 Superior short-term outcomes of laparoscopic vs. open
procedures have been reported, depending on type of surgery, oper-
ator experience and hospital volume, but few studies provide direct
measures of cardiac complications.30– 32 Benefit from laparoscopic
procedures is probably greater in elderly patients, with reduced
length of hospital stay, intra-operative blood loss, incidence of post-
operative pneumonia, time to return of normal bowel function, in-
cidence of post-operative cardiac complications, and wound infec-
tions.33 Few data are available for video-assisted thoracic surgery
(VATS), with no large, randomized trial comparing VATS with
open thoracic lung resection. In one study involving propensity-
score-matched patients, VATS lobectomy was associated with no
significant difference in mortality, but with significantly lower
rates of overall perioperative morbidity, pneumonia, and atrial
arrhythmia.34
Recommendations on the selection of surgical approach
and its impact on risk
Recommendations Classa Levelb Ref.c
It is recommended that patients 
should undergo pre-operative risk 
assessment independently of an 





In patients with AAA 55 mm, 
anatomically suited for EVAR, 
either open or endovascular aortic 
repair is recommended if surgical 
risk is acceptable.
I A 15–17
In patients with asymptomatic 
AAA who are unfit for open 
repair, EVAR, along with best 
medical treatment, may be 
considered.
IIb B 15,35
In patients with lower extremity 
artery disease requiring 
revascularization, the best 
management strategy should be 
determined by an expert team 
considering anatomy, 
comorbidities, local availability, and 
expertise.
IIa B 18




dSince laparoscopic procedures demonstrate a cardiac stress similar to that of open
procedures.
3.3 Functional capacity
Determination of functional capacity is a pivotal step in pre-
operative cardiac risk assessment and is measured in metabolic
equivalents (METs). One MET equals the basal metabolic rate. Ex-
ercise testing provides an objective assessment of functional cap-
acity. Without testing, functional capacity can be estimated from
the ability to perform the activities of daily living. One MET repre-
sents metabolic demand at rest; climbing two flights of stairs
demands 4 METs, and strenuous sports, such as swimming, .10
METS (Figure 1).
The inability to climb two flights of stairs or run a short distance
(,4 METs) indicates poor functional capacity and is associated
with an increased incidence of post-operative cardiac events. After
thoracic surgery, a poor functional capacity has been associated
with an increased mortality (relative risk 18.7; 95% CI 5.9–59);
however, in comparison with thoracic surgery, a poor functional
status was not associated with an increased mortality afterothernon-
cardiac surgery (relative risk 0.47; 95% CI 0.09–2.5).38 This may
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reflect the importance of pulmonary function—strongly related to
functional capacity—as a major predictor of survival after thoracic
surgery. These findings were confirmed in a study of 5939 patients
scheduled for non-cardiac surgery, in which the pre-operative func-
tional capacity measured in METs showed a relatively weak associ-
ation with post-operative cardiac events or death.39 Notably, when
functional capacity is high, the prognosis is excellent, even in the pres-
ence of stable IHD or risk factors;40 otherwise, when functional cap-
acity is poor or unknown, the presence and number of risk factors in
relation to the risk of surgery will determine pre-operative risk strati-
fication and perioperative management.
3.4 Risk indices
For two main reasons, effective strategies aimed at reducing the
risk of perioperative cardiac complications should involve cardiac
evaluation, using medical history before the surgical procedure,.
Firstly, patients with an anticipated low cardiac risk—after thorough
evaluation—can be operated on safely without further delay. It is
unlikely that risk-reduction strategies will further reduce the
perioperative risk. Secondly, risk reduction by pharmacological treat-
ment is most cost-effective in patients with a suspected increased
cardiac risk. Additional non-invasive cardiac imaging techniques are
tools to identify patients at higher risk; however, imaging techniques
should be reserved for those patients in whom test results would in-
fluence and change management. Clearly, the intensity of the pre-
operative cardiac evaluation must be tailored to the patient’s clinical
condition and the urgency of the circumstances requiring surgery.
When emergency surgery is needed, the evaluation must necessarily
be limited; however, most clinical circumstances allowtheapplication
of a more extensive, systematic approach, with cardiac risk evaluation
that is initially based on clinical characteristics and type of surgery
and then extended, if indicated, to resting electrocardiography
(ECG), laboratory measurements, or other non-invasive assessments.
Several risk indices have been developed during the past 30 years,
based on multivariate analyses of observational data, which
represent the relationship between clinical characteristics and peri-
operative cardiac mortality and morbidity. The indices developed
by Goldman et al. (1977),41 Detsky et al. (1986),42 and Lee et al.
(1999)43 have become well-known.
Although only a rough estimation, the older risk-stratification
systems may represent useful clinical tools for physicians in respect
of the need for cardiac evaluation, drug treatment, and assessment
of risk for cardiac events. The Lee index or ‘revised cardiac risk’
index, amodifiedversionof theoriginalGoldman index,wasdesigned
to predict post-operative myocardial infarction, pulmonary oedema,
ventricular fibrillation or cardiac arrest, and complete heart block.
This risk index comprises six variables: type of surgery, history
of IHD, history of heart failure, history of cerebrovascular disease,
pre-operative treatment with insulin, and pre-operative creatinine
.170 mmol/L (.2 mg/dL), and used to be considered by many clin-
icians and researchers to be the best currently available cardiac-risk
prediction index in non-cardiac surgery.
All of the above-mentioned risk indices were, however, developed
years ago and many changes have since occurred in the treatment of
IHD and in the anaesthetic, operative and perioperative management
of non-cardiac surgical patients. A new predictive model was recently
developed to assess the risk of intra-operative/post-operative myo-
cardial infarction orcardiacarrest, using the American College of Sur-
geons National Surgical Quality Improvement Program (NSQIP)
database.44 This NSQIP MICA model was built on the 2007 data
set, based on patients from 180 hospitals, and was validated with
the 2008 data set, both containing.200 000 patients and having pre-
dictability. The primary endpoint was intra-operative/post-operative
myocardial infarction or cardiac arrest up to 30 days after surgery.
Five predictors of perioperative myocardial infarction/cardiac
arrest were identified: type of surgery, functional status, elevated cre-
atinine (.130 mmol/L or .1.5 mg/dL), American Society of
Anesthesiologists (ASA) class (Class I, patient is completely healthy;
Class II, patient has mild systemic disease; Class III, patient has
severe systemic disease that is not incapacitating; Class IV, patient
has incapacitating disease that is a constant threat to life; and Class
V, a moribund patient who is not expected to live for 24 hours,
with or without the surgery), and age. This model is presented as
an interactive risk calculator (http://www.surgicalriskcalculator.
com/miorcardiacarrest) so that the risk can be calculated at the
bedside or clinic in a simple and accurate way. Unlike other risk
scores, the NSQIP model did not establish a scoring system but pro-
vides a model-based estimate of the probability of myocardial infarc-
tion/cardiac arrest for an individual patient. The risk calculator
performed better than the Lee risk index, with some reduction in
performance in vascular patients, although it was still superior;
however, some perioperative cardiac complications of interest to
clinicians, such as pulmonary oedema and complete heart block,
were not considered in the NSQIP model because those variables
were not included in the NSQIP database. By contrast, the Lee
index allows estimation of the risk of perioperative pulmonary
oedema and of complete heart block, in addition to death and
Functional capacity
Can you...
Take care of yourself?
Eat, dress,






at 3 to 5 km per h?
Can you...
Climb two flights of stairs
or walk up a hill?
Do heavy work 
around the house like
scrubbing floors of lifting 
or moving heavy
furniture?
Participate in strenuous 
sports like swimming, 





Greater than 10 METs
Figure 1 Estimated energy requirements for various activities.
Based on Hlatky et al. and Fletcher et al.36,37 km per h ¼ kilometres
per hour; MET ¼ metabolic equivalent.
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index-for-pre-operative-risk/). A recent systematic review of 24
studies covering .790 000 patients found that the Lee index discri-
minated moderately well patients at low vs. high risk for cardiac
events after mixed non-cardiac surgery, but its performance was
hampered when predicting cardiac events after vascular non-cardiac
surgery or predicting death.45 Therefore, the NSQIP and Lee risk
index models provide complementary prognostic perspectives and
can help the clinician in the decision-making process.
Risk models do not dictate management decisions but should be
regarded as one piece of the puzzle to be evaluated, in concert
with the more traditional information at the physician’s disposal.
3.5 Biomarkers
A biological marker, or ’biomarker’, is a characteristic that can be ob-
jectively measured and which is an indicator of biological processes.
In the perioperative setting, biomarkers can be divided into markers
focusing on myocardial ischaemia and damage, inflammation, and LV
function. Cardiac troponins T and I (cTnT and cTnI, respectively) are
the preferred markers for the diagnosis of myocardial infarction
because they demonstrate sensitivity and tissue specificity better
than other available biomarkers.46 The prognostic information is in-
dependent of—and complementary to—other important cardiac
indicators of risk, such as ST deviation and LV function. It seems
that cTnI and cTnT are of similar value for risk assessment in ACS
in the presence and absence of renal failure. Existing evidence sug-
gests that even small increases in cTnT in the perioperative period
reflect clinically relevant myocardial injury with worsened cardiac
prognosis and outcome.47 –49 The development of new biomarkers,
including high-sensitivity troponins, will probably furtherenhance the
assessment of myocardial damage.48 Assessment of cardiac tropo-
nins in high-risk patients, both before and 48–72 hours after major
surgery,may thereforebe considered.3 It should be noted that tropo-
nin elevation may also be observed in many other conditions; the
diagnosis of non-ST-segment elevation myocardial infarction
should never be made solely on the basis of biomarkers.
Inflammatory markers might pre-operatively identify those
patients with an increased risk of unstable coronary plaque;
however, in the surgical setting, no data are currently available on
how inflammatory markers would alter risk-reduction strategies.
B-type natriuretic peptide (BNP) and N-terminal pro-BNP
(NT-proBNP) are produced in cardiac myocytes in response to
increases in myocardial wall stress. This may occur at any stage of
heart failure, independentlyof the presence or absence of myocardial
ischaemia. Plasma BNP and NT-proBNP have emerged as important
prognostic indicators across many cardiac diseases in non-surgical
settings.50 Pre-operative BNP and NT-proBNP levels have additional
prognostic value for long-term mortality and for cardiac events after
major non-cardiac vascular surgery.51 –53
Data from prospective, controlled trials on the use of pre-
operative biomarkers are sparse. Based on the existing data, assess-
ment of serum biomarkers for patients undergoing non-cardiac
surgery cannot be proposed for routine use, but may be considered
in high-risk patients (METs ≤4 or with a revised cardiac risk index
value .1 for vascular surgery and .2 for non-vascular surgery).
Recommendations on cardiac risk stratification
Recommendations Classa Levelb Ref. c
Clinical risk indices are 
recommended to be used 
for peri-operative risk 
stratification.
I B 43,44
The NSQIP model or the 
Lee risk index are 




Assessment of cardiac 
troponins in high-risk 
patients, both before and 
48–72 hours after major 
surgery, may be 
considered.
IIb B 3,48,49
NT-proBNP and BNP 
measurements may be 
considered for obtaining 
independent prognostic 
information for peri-
operative and late cardiac 





sampling for risk 
stratification and to 
prevent cardiac events is 
not recommended.
III C
BNP ¼ B-type natriuretic peptide; NT-proBNP¼N-terminal pro-brain natriuretic
peptide.





Pre-operative non-invasive testing aims to provide information on
three cardiac risk markers: LV dysfunction, myocardial ischaemia,
and heart valve abnormalities, all of which are major determinants
of adverse post-operative outcome. LV function is assessed at rest,
and various imaging methods are available. For detection of myocar-
dial ischaemia, exercise ECG and non-invasive imaging techniques
may be used. Routine chest X-ray before non-cardiac surgery is
not recommended without specific indications. The overall theme
is that the diagnostic algorithm for risk stratification of myocardial is-
chaemia and LV function should be similar to that proposed for
patients in the non-surgical setting with known or suspected
IHD.56 Non-invasive testing should be considered not only for cor-
onary artery revascularization but also for patient counselling,
change of perioperative management in relation to type of surgery,
anaesthetic technique, and long-term prognosis.
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3.6.1 Non-invasive testing of cardiac disease
3.6.1.1 Electrocardiography
The 12-lead ECG is commonly performed as part of pre-operative
cardiovascular risk assessment in patients undergoing non-cardiac
surgery. In IHD patients, the pre-operative ECG offers important
prognostic information and is predictive of long-term outcome, inde-
pendent of clinical findings and perioperative ischaemia.57 However,
the ECG may be normal or non-specific in patients with myocardial
ischaemia or even with infarction.
Recommendations on routine pre-operative ECG
Recommendations Classa Levelb Ref.c
Pre-operative ECG is 
recommended for patients who 
have risk factor(s)d and are 
scheduled for intermediate- or 
high-risk surgery.
I C 57
Pre-operative ECG may be 
considered for patients who have 
risk factor(s) and are scheduled for 
low-risk surgery.
IIb C
Pre-operative ECG may be 
considered for patients who have 
no risk factors, are above 65 years 
of age, and are scheduled for 
intermediate-risk surgery.
IIb C
Routine pre-operative ECG is not 
recommended for patients who 
have no risk factors and are 






dClinical risk factors in Table 4.
3.6.1.2 Assessment of left ventricular function
Resting LV function can be evaluated before non-cardiac surgery
by radionuclide ventriculography, gated single photon emission
Recommendations on resting echocardiography in
asymptomatic patients without signs of cardiac disease
or electrocardiographic abnormalities
Recommendations Classa Levelb
Rest echocardiography may be 
considered in patients undergoing 
high-risk surgery.
IIb C
Routine echocardiography is not 
recommended in patients 





computed tomography (SPECT), echocardiography, magnetic res-
onance imaging (MRI) or multislice computed tomography (CT), all
with similar accuracy. Echocardiography is the most readily available
and versatile tool for evaluating ventricular function. Routine echo-
cardiography is not recommended for the pre-operative evaluation
of ventricular function but may be performed in asymptomatic
patients with high surgical risk.58 Pre-operative LV systolic dysfunc-
tion, moderate-to-severe mitral regurgitation, and increased aortic
valve gradients are associated with major cardiac events.59 The
limited predictive value of LV function assessment for perioperative
outcome may be related to the failure to detect severe underlying
IHD.
3.6.2 Non-invasive testing of ischaemic heart disease
Physical exercise, using a treadmill or bicycle ergometer, provides an
estimate of functional capacity, evaluates blood pressure and heart
rate response, and detects myocardial ischaemia through
ST-segment changes. The accuracy of exercise ECG varies signifi-
cantly among studies.56 Risk stratification with an exercise test is
not suitable for patients with limited exercise capacity, owing to
their inability to reach their target heart rate. Also, pre-existing
ST-segment abnormalities at rest—especially in precordial leads
V5 and V6—hamper reliable ST-segment analysis. A gradient of se-
verity in the test result relates to the perioperative outcome: the
onset of a myocardial ischaemic response at low exercise workloads
is associated with a significantly increased risk of perioperative and
long-term cardiac events. In contrast, the onset of myocardial ischae-
mia at high workloads is associated with only a minor risk increase,
but higher than a totally normal test. Pharmacological stress testing
with either nuclear perfusion imaging or echocardiography is more
suitable in patients with limited exercise tolerance.
The role of myocardial perfusion imaging for pre-operative risk
stratifications is well established. Inpatients with limited exercise cap-
acity, pharmacological stress (dipyridamole, adenosine, or dobuta-
mine) is an alternative stressor. Studies are performed both during
stress and at rest, to determine the presence of reversible defects,
reflecting jeopardized ischaemic myocardium or fixed defects,
reflecting scar or non-viable tissue.
The prognostic value of the extent of ischaemic myocardium, using
semi-quantitative dipyridamole myocardial perfusion imaging, has
been investigated in a meta-analysis of patients undergoing vascular
surgery.60 Study endpoints were perioperative cardiac death and
myocardial infarction. The authors included nine studies, totalling
1179 patients undergoing vascular surgery, with a 7% 30-day event
rate. In this analysis, reversible ischaemia in,20% of the LV myocar-
dium did not alter the likelihood of perioperative cardiac events, com-
pared with those without ischaemia. Patients with more extensive
reversible defects from 20–50% were at increased risk.
A second meta-analysis pooled the results of 10 studies evaluating
dipyridamole thallium-201 imaging in candidates for vascular surgery
over a 9-year period from 1985 to 1994.61 The 30-day cardiac death
or non-fatal myocardial infarction rates were 1% in patients with
normal test results, 7% in patients with fixed defects, and 9% in
patients with reversible defects on thallium-201 imaging. Moreover,
three of the 10 studies analysed used semi-quantitative scoring, dem-
onstrating a higher incidence of cardiac events in patients with two or
more reversible defects.
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Overall, the positive predictive value of reversible defects for peri-
operative death or myocardial infarction has decreased in more
recent studies. This is probably related to changes in perioperative
management and surgical procedures; however, because of the
high sensitivity of nuclear imaging studies for detecting IHD, patients
with a normal scan have an excellent prognosis.
Stress echocardiography using exercise or pharmacological
(dobutamine, dipyridamole) stress has been widely used for pre-
operative cardiac risk evaluation. The test combines information on
LV function at rest, heart valve abnormalities, and the presence and
extent of stress-inducible ischaemia.62 In one study, 530 patients
were enrolled to evaluate the incremental value of dobutamine
stress echocardiography (DSE) for the assessment of cardiac risk
before non-vascular surgery.63 Multivariate predictors of post-
operative events in patients with ischaemia were found to be a
history of heart failure (OR 4.7; 95% CI 1.6–14.0) and ischaemic
threshold ,60% of age-predicted maximal heart rate (OR 7.0; 95%
CI 2.8–17.6). DSE has some limitations: it should not, for example,
be used in patients with severe arrhythmias, significant hypertension,
large thrombus-laden aortic aneurysms, or hypotension.
In general, stress echocardiography has a high negative predictive
value and a negative test is associated with a very low incidence of
cardiac events in patients undergoing surgery; however, the positive
predictive value is relatively low (between 25% and 45%); this means
that the postsurgical probability of a cardiac event is low, despite wall
motion abnormality detection during stress echocardiography.
A negative DSE, performed before scheduled aortic surgery, does
not, however, rule out post-operative myocardial necrosis.64 Failure
to achieve target heart rate is not uncommon, despite an aggressive
DSE regimen. A negative DSE without resting wall motion abnormal-
ities has excellent negative predictive value, regardless of the heart
rate achieved. Patients with resting wall motion abnormalities are
at increased risk for perioperative events, even if ischaemia cannot
be induced.65
In a meta-analysis of 15 studies comparing dipyridamole thallium-201
imaging and DSE for risk stratification before vascular surgery, it was
demonstrated that the prognostic value of stress imaging abnormalities
for perioperative ischaemic events is similar with both pharmacological
stressors, but that the accuracy varies with IHD prevalence.61 In patients
with a low prevalence of IHD, the diagnostic accuracy is reduced, com-
pared with those with a high incidence of IHD.
Cardiovascular magnetic resonance (CMR) imaging can be used
for detection of ischaemia; both perfusion and wall motion can be
detected during stress and at rest.66 Its accuracy in assessment
of ischaemia is high, with a sensitivity of 83% and a specificity of
86% when wall motion is used (14 studies; 754 patients). When per-
fusion is assessed (24 studies; 1516 patients), its sensitivity was 91%
and specificity 81%. When evaluated prospectively in a multicentre
study, the sensitivity was 67% and the specificity was 61%.67 There
are limited data on CMR in the pre-operative setting; in one study
dobutamine stress CMR was used in 102 patients undergoing
major non-cardiac surgery; in multivariate analysis, myocardial is-
chaemia was the strongest predictor of perioperative cardiac
events (death, myocardial infarction, and heart failure).68 Currently
no data are available in the setting of pre-operative risk stratification.
Computed tomography can be used to detect coronary
calcium, which reflects coronary atherosclerosis, and CT angiog-
raphy is useful for excluding coronary artery disease (CAD) in
patients who are at low risk of atherosclerosis.69 Currently, no data
are available in the setting of pre-operative risk stratification. All
the various imaging tests have their intrinsic risks and these need to
be taken into account when they are used.70
Recommendations on imaging stress testing before
surgery in asymptomatic patients
Recommendations Classa Levelb
Imaging stress testing is recommended 
before high-risk surgery in patients with 
more than two clinical risk factors and 
poor functional capacity (<4 METs).c
I C
Imaging stress testing may be considered 
before high- or intermediate-risk 
surgery in patients with one or two 
clinical risk factors and poor functional 
capacity (<4 METs).c
IIb C
Imaging stress testing is not 
recommended before low-risk surgery, 
regardless of the patient’s clinical risk.
III C
MET ¼ metabolic equivalent
aClass of recommendation.
bLevel of evidence.
cClinical risk factors in Table 4.
How can these data contribute to a practical algorithm? Testing
should only be performed if its results might influence perioperative
management. Patients with extensive stress-induced ischaemia re-
present a high-risk population in whom standard medical therapy
appears insufficient to prevent a perioperative cardiac event. Pre-
operative testing is recommended in the case of high-risk surgery
in patients with poor functional capacity (,4 METS) and more
than two of the clinical risk factors listed in Table 4, but may also be
considered in patients with fewer than three of these risk factors. Im-
portantly, pre-operative testing might delay surgery. A similar recom-
mendation is made for intermediate-risk surgery patients, although
no data from randomized trials are available. Considering the low
event rate of patients scheduled for low-risk surgery, it is unlikely
that test results will alter perioperative management in stable
cardiac patients.
Table 4 Clinical risk factors according to the revised
cardiac risk index43
aAccording to the universal definition of myocardial infarction.49
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3.7 Invasive coronary angiography
Coronary angiography is a well-established, invasive, diagnostic
procedure but is rarely indicated for assessing the risk of patients
undergoing non-cardiac surgery. There is a lack of information
from randomized clinical trials, relating to its usefulness in patients
scheduled for non-cardiac surgery. Also, adopting an invasive cor-
onary angiography assessment may cause an unnecessary and un-
predictable delay in an already planned surgical intervention, as
well as adding an independent procedural risk to the overall risk.
Despite the fact that CAD may be present in a significant number
of patients requiring non-cardiac surgery, indications for pre-
operative coronary angiography and revascularization are similar
to angiography indications in the non-surgical setting.56,72 – 75 Pre-
operative treatment of myocardial ischaemia, either medically or
with intervention, is recommended whenever non-cardiac
surgery can be delayed.
Recommendations on pre-operative coronary
angiography
Recommendations Classa Levelb Ref.c
Indications for pre-operative 
coronary angiography and 
revascularization are similar 
to those for the non-surgical 
setting.
I C 56
Urgent angiography is 
recommended in patients 





Urgent or early invasive 
strategy is recommended in 
patients with NSTE-ACS
requiring non-urgent, non-
cardiac surgery according to 
risk assessment.
I B 73
Pre-operative angiography is 
recommended in patients 
with proven myocardial 
ischaemia and unstabilized 
chest pain  (Canadian 
Cardiovascular Society Class 
III–IV) with adequate medical 




may be considered in stable 




Pre-operative angiography is 










The stress of surgery and anaesthesia may trigger ischaemia through
an increase in myocardial oxygen demand, a reduction in myocardial
oxygen supply, or both. Besides specific risk-reduction strategies
adapted to patient characteristics and type of surgery, pre-operative
evaluation can check and optimize the control of cardiovascular risk
factors.
4.1.1 Beta-blockers
Concerns were raised over a number of studies of the Dutch Echo-
cardiographic Cardiac Risk Evaluation Applying Stress Echocardiog-
raphy (DECREASE) family,77 and the results of these studies were
not included in the present Guidelines.
The main rationale for perioperative beta-blocker use is to de-
crease myocardial oxygen consumption by reducing heart rate,
leading to a longer diastolic filling period and decreased myocardial
contractility. Additional cardioprotective factors have been sug-
gested; however, the answer to whether or not this translates into
clinical benefit requires randomized trials analysing the incidence of
cardiovascular events. Six randomized trials evaluating the effect of
perioperative beta-blockade on clinical endpoints have been pub-
lished in English in peer-reviewed journals (Table 5).78 –83
Two trials targeted patients at high risk for perioperative compli-
cations relating to the type of surgery, the presence of IHD, or risk
factors for perioperative cardiac complications.79,83 Three other
trials did not require clinical risk factors, except for diabetes in one
case.80 –82 The Peri-Operative ISchemic Evaluation (POISE) trial
covered a wide spectrum of risk of perioperative cardiac complica-
tions.78 One trial randomized 200 patients with at least two IHD
risk factors or with known IHD, who were scheduled for non-cardiac
surgery under general anaesthesia, including 40% for major vascular
surgery.83 Atenolol was associated with a significant decrease in
overall mortality at 6 months, which was sustained for up to 2
years; however, seven in-hospital deaths, five in the atenolol group
and two in the placebo group, were not taken into account. The Peri-
Operative Beta-BLockadE (POBBLE) trial randomized 103 low-risk
patients undergoing elective infrarenal vascular surgery to metopro-
lol tartrate or placebo,82 resulting in a similar incidence of death,
myocardial infarctionor strokeat30days (13%and 15%, respectively;
P¼ 0.78). Patients at low cardiac risk and thosewith a historyof myo-
cardial infarction within the past 2 years were excluded. The
Metoprolol after Vascular Surgery (MaVS) trial randomized 497
patients undergoing abdominal or infra-inguinal vascular surgery
to metoprolol succinate or placebo.80 The combined incidence
of death, myocardial infarction, heart failure, arrhythmias, or stroke
at 30 days was similar (10.2% and 12.0%, respectively; P ¼ 0.57).
The revised cardiac risk index was ≤2 in 90% of patients and ≤1
in 60%.
The Diabetes Post-Operative Mortality and Morbidity (DIPOM)
trial randomized 921 patients with diabetes, age.39 years, and dur-
ation of surgery of.1 hour (39% low-risk surgery) to receive meto-
prolol succinate or placebo.81 The combined incidence of death,
myocardial infarction, unstable angina, or heart failure at 30 days
was again similar (6% and 5%, respectively; P ¼ 0.66); however,
only 54% of patients had a history of IHD or an additional cardiac
risk factor, and underwent high- or intermediate-risk surgery.
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The POISE trial randomized8351 patients to metoprolol succinate
or placebo.78 Patients were aged ≥45 years and had known CVD, or
at least three of seven clinical risk factors for high-risk surgery, or
were scheduled for major vascular surgery. Treatment consisted of
metoprolol succinate 100 mg 2–4 hours before surgery, 100 mg
during the first 6 hours after surgery, but medication was withheld
if systolic blood pressure dipped below 100 mm Hg. Maintenance
therapy started 12 hours later, bringing the total dose of metoprolol
succinate in the first24 hours to400 mg in some patients. Therewas a
17% decrease in the primary composite endpoint of death, myocar-
dial infarction, or non-fatal cardiac arrest at 30 days (5.8% vs. 6.9%;
P¼ 0.04); however, the 30% decrease in non-fatal myocardial infarc-
tion (3.6% vs. 5.1%; P, 0.001) was offset by a 33% increase in total
mortality (3.1% vs. 2.3%; P¼ 0.03) and a doubling of stroke incidence
(1.0% vs. 0.5%; P ¼ 0.005). Hypotension was more frequent with
metoprolol (15.0% vs. 9.7%; P , 0.0001). Post-hoc analysis showed
that hypotension carried the greatest attributable risk of death and
stroke.84
Eight meta-analyses have pooled 9, 25, 5, 11, 6, 8, 22, and 33 pub-
lished, randomized trials onperioperativebeta-blockers, totalling, re-
spectively, 10 529, 12 928, 586, 866, 632, 2437, 2057, and 12 306
patients.85– 92 Four meta-analyses showed a significant reduction in
perioperative myocardial ischaemia and myocardial infarction in
patients receiving beta-blockers,88,89,91,92 this being more marked
in high-risk patients. Two meta-analyses showed no significant reduc-
tion in perioperative myocardial infarction or cardiac mortality in
patients receiving beta-blockers.87,90 These meta-analyses (except
the two most recent ones)85,86 have been criticized because of het-
erogeneity of included studies and types of surgery, inclusion of
studies of the DECREASE family, imprecision regarding patients’
cardiac risk profiles, and variable timing of beta-blocker administra-
tions, doses, and targets.93 The recent POISE trial had the greatest
weight in all of these analyses. In POISE, all-cause mortality increased
by 33% in patients receiving beta-blockers; perioperative death
in patients receiving metoprolol succinate were associated with
perioperative hypotension, bradycardia, and stroke. A history of
cerebrovascular disease was associated with an increased risk of
stroke. Hypotension was related to high-dose metoprolol without
dose titration.
In a meta-analysis that excluded the DECREASE trials,85 peri-
operative beta-blockade was associated with a statistically significant
27% (95% CI 1–60) increase in mortality (nine trials, 10 529 patients)
but the POISE trial again largely explained this result,78 and also the
reduced incidence of non-fatal myocardial infarction and increased
incidence of non-fatal strokes. Another recent meta-analysis, involv-
ing 12 928 patients, examined the influence of beta-blockade on all-
Table 5 Summary of randomized, controlled trials evaluating the effect of peri-operative beta-blockade on post-
operative mortality and non-fatal myocardial infarction
BBSA ¼ Beta-Blocker in Spinal Anesthesia; DIPOM ¼ Diabetic Postoperative Mortality and Morbidity; IHD ¼ ischaemic heart disease; MaVS ¼ Metoprolol after Vascular Surgery;
MI ¼ myocardial infarction; POBBLE ¼ PeriOperative Beta-BlockadE; POISE ¼ PeriOperative ISchemic Evaluation.









cause and cardiovascular mortality according to surgery-specific risk
groups, beta-blocker treatment duration, and whether beta-
blockade was titrated to targeted heart rate.86 The benefit of beta-
blockade was found in five high-risk surgery studies and in six
studies using titration to targeted heart rate, of which one and two
trials, respectively, were of the DECREASE family.
Discrepancies in the effects of beta-blockers can be explained by
differences in patient characteristics, type of surgery, and the
methods of beta-blockade (timing of onset, duration, dose titration,
and type of drug). Also, problems arose by the inclusion of trials not
designed to assess the effect on perioperative cardiac risk or which
used only a single beta-blocker dose before anaesthesia, without
continuation after surgery.87 Two meta-analyses suggested that dif-
ferences between trials on the cardioprotective effect of beta-
blockers could be attributed to variability in heart rate response.86,94
In particular, the decrease in post-operative myocardial infarction
was highly significant, with tight heart rate control.
In patients with clinical risk factors undergoing high-risk
(mainly vascular) surgery, randomized trials, cohort studies, and
meta-analyses provide some evidence supporting a decrease in
cardiac mortality and myocardial infarction with beta-blockers
(mainly atenolol). Perioperative beta-blockade is also cost-effective
in these patients; however, patients with myocardial ischaemia as
demonstrated by stress testing are at high risk of perioperative
cardiac complications despite perioperative beta-blocker use.
Conversely, inpatientswithoutclinical risk factors, randomized trials
and cohort studies suggest that perioperative beta-blockade does not
decrease the risk of cardiac complications and may even increase this
risk. A possible increase in mortality has been suggested by a retro-
spective cohort.95 Bradycardia and hypotension may be harmful in
patients with atherosclerosis, and enhance the risk of stroke and
death. Also, perioperative beta-blocker administration may enhance
post-operative delirium in patients undergoing vascular surgery.
One cannot justify exposing low-risk patients to potential adverse
effects in the absence of proven benefit. The issue remains debatable
in intermediate-risk patients, i.e. those with one or two clinical risk
factors. Increased mortality following pre-operative beta-blocker
withdrawalhasbeen reported in fourobservational studies.96–99 Beta-
blockers should be continued when prescribed for IHD or arrhyth-
mias. When beta-blockers are prescribed for hypertension, the
absence of evidence for a perioperative cardioprotective effect with
other antihypertensive drugs does not support a change of therapy.
Beta-blockers should not be withdrawn in patients treated for stable
heart failure due to LV systolic dysfunction. In decompensated heart
failure, beta-blocker therapy should be adjusted to the clinical condi-
tion. If possible, non-cardiac surgery should be deferred so it can be
performed under optimal medical therapy in a stable patient. Contra-
indications to beta-blockers (asthma, severe conduction disorders,
symptomatic bradycardia, and symptomatic hypotension) should be
respected. In patients with intermittent claudication, beta-blockers
have not been shown to worsen symptoms and are therefore not
contra-indicated. In the absence of contra-indications, beta-blocker
dose should be slowly up-titrated, starting at a low dose of a beta1-
selective agent, to achieve a resting heart rate between 60 and 70
beats per minute (bpm). Beta1-selective blockers without intrinsic
sympathomimetic activity are favoured and evidence exists that
atenolol and bisoprolol are superior to metoprolol,97,100–102 possibly
due to theCYP2D6-dependentmetabolismofmetoprolol.Trialsusing
metoprololdid not showaclearbenefit.78,80–82 A recent single-centre
cohort study in 2462 pair-matched patients suggested that metoprolol
or atenolol (analysed together) are associated with increased risk of
post-operative stroke, compared with bisoprolol.102
Recommendations on beta-blockers
Recommendations Classa Levelb Ref.c
Peri-operative continuation of beta-
blockers is recommended in 
patients currently receiving this 
medication.
I B 96–99
Pre-operative initiation of beta-
blockers may be considered in 
patients scheduled for high-risk 
surgery and who have 2 clinical 




Pre-operative initiation of beta-
blockers may be considered in 





When oral beta-blockade is 
initiated in patients who undergo 
non-cardiac surgery, the use of 
atenolol or bisoprolol as a first 




Initiation of peri-operative high-
dose beta-blockers without 
titration is not recommended.
III B 78
Pre-operative initiation of beta-
blockers is not recommended in 
patients scheduled for low-risk 
surgery.
III B 86,97




dTreatment should ideally be initiated between 30 days and (at least) 2 days before
surgery, starting at a low dose, and should be continued post-operatively.83,98,103
The target is a resting heart rate 60–70 bpm,86 and systolic blood pressure
.100 mm Hg.79,83
Initiation of treatment and the optimal choice of beta-blocker dose
are closely linked. Bradycardia and hypotension should be avoided. It
is important to prevent overtreatment with fixed, high, initial doses,
and doses should be decreased if this occurs. Beta-blocker dose
should be slowly up-titrated and tailored to appropriate heart rate
and blood pressure targets, requiring that treatment be initiated
ideally more than 1 day (when possible at least 1 week and up to
30 days) before surgery, starting with a low dose.83,98,103 In patients
with normal renal function, atenolol treatment should start with a
50 mg daily dose, then adjusted before surgery to achieve a resting
heart rate of 60-70 bpm86 with systolic blood pressure .100 mm
Hg.83 The heart rate goal applies to the whole perioperative
period, using intravenous administration when oral administration
is not possible. High doses should be avoided, particularly immediate-
ly before surgery. A retrospective study suggests that intra-operative
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mean arterial pressure should remain above 55 mm Hg.104 Post-
operative tachycardia should firstly lead to treatment of the
underlying cause—for example, hypovolaemia, pain, blood loss, or
infection—rather than simply increasing the beta-blocker dose.
When beta-blockers are indicated, the optimal duration of peri-
operative beta-blockade cannot be derived from randomized trials.
The occurrence of delayed cardiac events indicates a need to con-
tinue beta-blocker therapy for several months. For patients testing
positive for pre-operative stress, long-term beta-blocker therapy
should be used.
A high priority needs to be given to new, randomized, clinical trials
to better identify which patients derive benefit from beta-blocker
therapy in the perioperative setting, and to determine the optimal
method of beta-blockade.105
4.1.2 Statins
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) arewidelyprescribed inpatientswithorat riskof IHD.Patients
with non-coronary atherosclerosis (carotid, peripheral, aortic, renal)
should receive statin therapy for secondary prevention, irrespective
of non-cardiac surgery. Statins also induce coronary plaque stabiliza-
tion through pleiotropic effects, which may prevent plaque rupture
and subsequent myocardial infarction in the perioperative period.
Multiple observational studies have suggested that perioperative
statin use has a beneficial effect on the 30-day rate of death or myocar-
dial infarction, and on long-term mortality and cardiovascular event
rates.107–110 In a prospective, randomized, controlled trial, 100
patients scheduled for vascular surgery were allocated to 20 mg of
either atorvastatin or placebo once daily for 45 days, irrespective of
their serum cholesterol concentrations.111 At 6-month follow-up,
atorvastatin significantly reduced the incidence of cardiac events (8%
vs. 26%; P ¼ 0.03). In patients in whom statins were introduced
before intervention, two meta-analyses showed a significant reduction
in the risk of post-operative myocardial infarction following invasive
procedures,112,113 however, thesemeta-analyses includedmoreclinic-
al trials relating to cardiac surgeryor percutaneous procedures than to
non-cardiac surgery. All-cause post-operative mortality was not
reduced in most series, except in one observational study that used
propensity score adjustment to account for differences inpatient char-
acteristics according to the treatment.114 A recent Cochrane review
focusing onvascular surgery in statin-naı¨ve patients did notfind any sig-
nificant difference between statin-treated and control groups for the
separate endpoints of all-cause mortality, cardiovascular mortality,
and myocardial infarction, but these endpoints were assessed in only
178 patients.115 Statins have also been associated with a decreased
riskofcomplicationsafterendovascular repairofAAAandadecreased
risk of stroke after carotid stenting.116,117
Observational series suggest that perioperative statin therapy is
also associated with a lower risk of acute renal failure and with
lower mortality in patients experiencing post-operative complica-
tions or multiple organ dysfunction syndrome.114 Statins may de-
crease the risk of post-operative atrial fibrillation (AF) following
major non-cardiac surgery.
Statin withdrawal more than four days after aortic surgery is asso-
ciated with a three-fold higher risk of post-operative myocardial is-
chaemia.118 A potential limitation of perioperative statin use is the
lack of a parenteral formulation; therefore, statins with a long half-life
(e.g. atorvastatin) or extended release formulations (e.g. lovastatin)
may be favoured to bridge the period immediately after surgery
when oral intake is not feasible.
A concern relating to the use of perioperative statin therapy
has been the risk of statin-induced myopathy and rhabdomyolysis.
Perioperatively, factors increasing the risk of statin-induced
myopathy are numerous, e.g. the impairment of renal function after
major surgery, and multiple drug use during anaesthesia. Early intro-
duction of statins allows for better detection of potential side-effects.
According to current guidelines, most patients with peripheral
artery disease (PAD) should receive statins. If they have to undergo
open vascular surgery or endovascular intervention, statins should
be continued afterwards. In patients not previously treated, statins
should ideally be initiated at least 2 weeks before intervention
for maximal plaque-stabilizing effects and continued for at least
1 month after surgery. In patients undergoing non-vascular surgery,
there is no evidence to support pre-operative statin treatment if
there is no other indication.
Recommendations on statins
Recommendations Classa Levelb Ref.c
Peri-operative continuation of 
statins is recommended, 
favouring statins with a long 
half-life or extended-release 
formulation.
I C
Pre-operative initiation of 
statin therapy should be 
considered in patients 
undergoing vascular surgery, 








Nitroglycerine is well known for reversing myocardial ischaemia. The
effect of perioperative intravenous nitroglycerine on perioperative
ischaemia is a matter of debate and no effect has been demonstrated
on the incidence of myocardial infarction or cardiac death. Also peri-
operative use of nitroglycerine may pose a significant haemodynamic
risk to patients, since decreased pre-load may lead to tachycardia and
hypotension.
4.1.4 Angiotensin-converting enzyme inhibitors and
angiotensin-receptor blockers
Independently of the blood pressure-lowering effect, angiotensin con-
verting enzyme inhibitors (ACEIs) preserve organ function; however,
data from an observational study suggested that, regardless of the pre-
scription of beta-blockers and statins, ACEIs did not decrease the fre-
quency of 30-day or 1-year death or cardiac complications after
major vascular surgery in high-risk patients (revised cardiac index
≥3).110 Despite the lack of specific data on angiotensin-receptor
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blockers (ARBs), the following recommendations apply to ACEIs and
ARBs, given their numerous common pharmacological properties.
Additionally, perioperative use of ACEIs or ARBs carries a risk of
severe hypotension under anaesthesia, in particular following induc-
tion and concomitant beta-blocker use. Hypotension is less frequent
when ACEIs are discontinued the day before surgery. Although this
remains debatable, ACEIs withdrawal should be considered 24
hours before surgery when they are prescribed for hypertension.
They should be resumed after surgery as soon as blood volume
and pressure are stable. The risk of hypotension is at least as high
with ARBs as with ACEIs, and the response to vasopressors may
be impaired. In patients with LV systolic dysfunction, who are in a
stable clinical condition, it seems reasonable to continue treatment
with ACEIs under close monitoring during the perioperative
period. When LV dysfunction is discovered during pre-operative
evaluation in untreated patients in a stable condition, surgery
should if possible be postponed, to allow for diagnosis of the under-
lying cause and the introduction of ACEIs and beta-blockers.
Recommendations on use of ACEIs and ARBs
Recommendations Classa Levelb
Continuation of ACEIs or ARBs, 
under close monitoring, should be 
considered during non-cardiac surgery 
in stable patients with heart failure 
and LV systolic dysfunction.
IIa C
Initiation of ACEIs or ARBs should be 
considered at least 1 week before 
surgery in cardiac-stable patients with 
heart failure and LV systolic 
dysfunction.
IIa C
Transient discontinuation of ACEIs or 
ARBs before non-cardiac surgery in 
hypertensive patients should be 
considered.
IIa C
ACEI ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin receptor
blocker; LV ¼ left ventricular.
aClass of recommendation.
bLevel of evidence.
4.1.5 Calcium channel blockers
The effect of calcium channel blockers on the balance between myo-
cardial oxygen supply and demand makes them theoretically suitable
for risk-reduction strategies. It is necessary to distinguish between
dihydropyridines, which do not act directly on heart rate, and diltia-
zem or verapamil, which lower the heart rate.
The relevance of randomized trials assessing the perioperative
effect of calcium channel blockers is limited by their small size, lack
of risk stratification, and the absence of systematic reporting of
cardiac death and myocardial infarction. A meta-analysis pooled 11
randomized trials totalling 1007 patients. All patients underwent
non-cardiac surgery under calcium channel blocker treatment.
There was a significant reduction in the number of episodes of myo-
cardial ischaemia and supraventricular tachycardia (SVT) in the
pooled analyses; however, the decrease in mortality and myocardial
infarction reached statistical significance only when both endpoints
were combined in a composite of death and/or myocardial infarction
(relative risk 0.35; 95% CI 0.08–0.83; P , 0.02). Subgroup analyses
favoured diltiazem. Another study in 1000 patients undergoing
acute or elective aortic aneurysm surgery showed that dihydropyri-
dine use was independently associated with an increased incidence of
perioperative mortality.119 The use of short-acting dihydropyri-
dines—in particular, nifedipine capsules—should be avoided.
Thus, although heart rate-reducing calcium channel blockers are
not indicated in patients with heart failure and systolic dysfunction,
the continuation or introduction of heart rate-reducing calcium
channel blockers may be considered in patients who do not tolerate
beta-blockers. Additionally, calcium channel blockers should be con-
tinued during non-cardiac surgery in patients with vasospastic angina.
4.1.6 Alpha2 receptor agonists
Alpha2 receptor agonists reduce post-ganglionic noradrenaline
output and might therefore reduce the catecholamine surge during
surgery. The European Mivazerol trial randomized 1897 patients
with IHD who underwent intermediate- or high-risk non-cardiac
surgery. Mivazerol did not decrease the incidence of death or myo-
cardial infarction in the whole population; however, there was a re-
duction of post-operative death or myocardial infarction observed
in a sub-population of 904 patients undergoing vascular surgery.
The international Peri-Operative ISchemic Evaluation 2 (POISE-2)
trial randomized 10 010 patients undergoing non-cardiac surgery
to clonidine or placebo. Clonidine did not reduce the rate of death
or non-fatal myocardial infarction in general, or in patients undergo-
ing vascular surgery (relative risk 1.08; 95% Cl 0.93–1.26; P ¼ 0.29).
On the other hand, clonidine increased the risk of clinically important
hypotension (relative risk 1.32; 95% Cl 1.24–1.40; P , 0.001) and
non-fatal cardiac arrest (relative risk 3.20; 95% Cl 1.17–8.73; P ¼
0.02).120 Therefore, alpha2 receptor agonists should not be adminis-
tered to patients undergoing non-cardiac surgery.
4.1.7 Diuretics
Diuretics are frequently used in patients with hypertension or heart
failure. In general, diuretics for hypertension should be continued to
the day of surgery and resumed orally when possible. If blood pres-
sure reduction is required before oral therapy can be continued,
other antihypertensive agents may be considered. In heart failure,
dosage increase should be considered if symptoms or signs of fluid
retention are present. Dosage reduction should be considered in
patients with hypovolaemia, hypotension, or electrolyte distur-
bances. In general, diuretic treatment—if necessary to control
heart failure—should be continued to the day of surgery and
resumed orally when possible. In the perioperative period, volume
status in patients with heart failure should be monitored carefully
and optimized by loop diuretics or fluids.
The possibility of electrolyte disturbance should be considered in
any patient receiving diuretics. Hypokalaemia is reported to occur in
up to 34% of patients undergoing surgery (mostly non-cardiac). It is
well known to significantly increase the risk of ventricular fibrillation
and cardiac arrest in cardiac disease. In a study of 688 patients with
cardiac disease undergoing non-cardiac surgery, hypokalaemia was
independently associated with perioperative mortality. Importantly,
the use of K+ and Mg++-sparing aldosterone antagonists reduces
the risk of mortality in severe heart failure. Special attention should
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be given to patients taking diuretics and patients prone to developing
arrhythmias. Any electrolyte disturbance—especially hypokalaemia
and hypomagnesaemia—should be corrected in due time before
surgery. Acute pre-operative repletion in asymptomatic patients
may be associated with more risks than benefits; thus, minor asymp-
tomatic electrolyte disturbances should not delay acute surgery.
4.2 Perioperative management in patients
on anti-platelet agents
4.2.1 Aspirin
Perioperative evaluation of the impact of aspirin continuation or ces-
sation on serious cardiovascularevents or bleeding has disclosed con-
troversial results with, on the one hand, a reduction of intra- and
perioperative stroke—but without influence on myocardial infarction
during non-cardiac surgery—and, on the other hand, no statistical sig-
nificance for the combined endpoint of vascular events. Additionally,
concerns of promoting perioperative haemorrhagic complications
have often led to the discontinuation of aspirin in the perioperative
period. A large meta-analysis, including 41 studies in 49 590 patients,
which compared peri-procedural withdrawal vs. bleeding risks of
aspirin, concluded that the risk of bleeding complications with
aspirin therapy was increased by 50%, but that aspirin did not lead
to greater severity of bleeding complications.121 In subjects at risk
of—or with proven—IHD, aspirin non-adherence/withdrawal
tripled the risk of major adverse cardiac events.
The POISE-2 trial randomized 10 010 patients undergoing non-
cardiac surgery to aspirin or placebo.122 The patients were stratified
according to whether they had not been taking aspirin before the
study (initiation stratum, with 5628 patients) or they were already on
an aspirin regimen (continuation stratum, with 4382 patients). In the
POISE-2 trial, aspirin was stopped at least three days (but usually
sevendays)before surgery. Patients less than sixweeksafterplacement
of a bare metal coronary stent, or less than one year after placement of
a drug-eluting coronary stent, were excluded from the trial and the
number of stented patients outside these time intervals was too
small todrawfirmconclusionsasto therisk–benefitratio.Additionally,
only 23% of the study population had known prior CAD and patients
undergoing carotid endarterecomy surgery were excluded. Patients
started taking aspirin (at a dose of 200 mg) or placebo just before
surgery and continued it daily (at a dose of 100 mg) for 30 days in
the initiation stratum and for 7 days in the continuation stratum, after
which they resumed their regular aspirin regimen. Aspirin did not
reduce the rates of death or non-fatal myocardial infarction at 30
days (7.0% in the aspirin group vs. 7.1% in the placebo group; hazard
ratio 0.99; 95% CI 0.86–1.15; P ¼ 0.92). Major bleeding was more
common in the aspirin group than in the placebo group (4.6% vs.
3.8%, respectively; hazard ratio 1.23; 95% CI 1.01–1.49; P ¼ 0.04).
The primary and secondary outcome results were similar in the two
aspirin strata. The trial results do not support routine use of aspirin
in patients undergoing non-cardiac surgery, but it is uncertain
whether patients with a low perioperative bleeding risk and a high
risk of thrombo-embolic events could benefit from low-dose aspirin.
Aspirin should be discontinued if the bleeding risk outweighs the po-
tential cardiovascular benefit.121,123–125 For patients undergoing
spinal surgeryorcertainneurosurgicalorophthalmologicaloperations,
it is recommended that aspirin be discontinued for at least seven days.
In conclusion, the use of low-dose aspirin in patients undergoing
non-cardiac surgery should be based on an individual decision,
which depends on the perioperative bleeding risk, weighed against
the risk of thrombotic complications.
4.2.2 Dual anti-platelet therapy
Five to twenty-five percent of patients with coronary stents require
non-cardiac surgery within 5 years following stent implantation. The
prognosisof stent thrombosisappearstobeworse than fordenovocor-
onary occlusion, and premature cessation of dual anti-platelet therapy
(DAPT) in patients with recent coronary stent implantation is the most
powerful predictor for stent thrombosis. The consequences of stent
thrombosis will vary according to the site of stent deployment, e.g.
thrombosis of a left main stem stent is, in most cases, fatal.
The management of anti-platelet therapy, in patients who have
undergone recent coronary stent treatment and are scheduled for
non-cardiac surgery, should be discussed between the surgeon and
the cardiologist, so that thebalancebetween theriskof life-threatening
surgical bleeding on anti-platelet therapy—best understood by the
surgeon—and the risk of life-threatening stent thrombosis off
DAPT—best understood by the cardiologist—can be considered.
The ‘standard’ duration for DAPT after bare-metal stenting (BMS) is
different to that for drug-eluting stent (DES) treatment .126
To reduce risk of bleeding and transfusion, current Guidelines rec-
ommend delaying elective non-cardiac surgery until completion of
the full course of DAPT and, whenever possible, performing surgery
without discontinuation of aspirin.74 Patients who have undergone a
previous percutaneous coronary intervention (PCI) may be at higher
risk of cardiac events during or after subsequent non-cardiac surgery,
particularly in cases of unplanned or urgent surgery following coronary
stenting. While non-cardiac surgery performed early after balloon
angioplasty is not associated with an increased risk of cardiac
events,127 stenting dramatically changes the scenario. Accordingly,
mortality rates of up to 20% were reported in relation to perioperative
stent thrombosis when surgery was performed within weeks following
coronary stenting and DAPT was discontinued.128 Therefore, elective
surgery should be postponed for a minimum of 4 weeks and ideally for
up to 3 months after BMS implantation. Importantly, whenever pos-
sible, aspirin should be continued throughout surgery.129 In 2002,
DES were introduced in Europe and became widely accepted as an ef-
ficient tool for reducing in-stent re-stenosis; however, the major draw-
back of the first-generation DES was the need for prolonged DAPT
(aspirin plus clopidogrel) for 12 months. A higher risk of non-cardiac
surgery early after DES placement has been reported,126 and a
higher risk for major adverse cardiac events has also been shown
during the first weeks after non-cardiac surgery in patients with
implanted stents.126,130 But, for the new-generation (second- and
third-generation) DES, routine extension of DAPT beyond 6 months
is no longer recommended based on currently available data. Obser-
vational data from new-generation zotarolimus-eluting and everoli-
mus-eluting stents suggest that even shorter durations of DAPT may
be sufficient,131 and a randomized study showed a similar outcome
in patients treated with 3 and 12 months of DAPT after PCI.132
In patients undergoing myocardial revascularization for high-risk
ACS, DAPT treatment is recommended for 1 year irrespective of
stent type. Overall, in patients undergoing non-cardiac surgery
after recent ACS or stent implantation, the benefits of early
surgery for a specific pathology (e.g. malignant tumours, vascular an-
eurysm repair) should be balanced against the risk of stent throm-
bosis and the strategy should be discussed.
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In summary, it is recommended that DAPT be administered for at
least 1 month after BMS implantation in stable CAD,133 for 6 months
after new-generation DES implantation,133 and for up to 1 year in
patients after ACS, irrespective of revascularization strategy.133 Im-
portantly, a minimum of 1 (BMS) to 3 (new-generation DES)
months of DAPT might be acceptable, independently of the acute-
ness of coronary disease, in cases when surgery cannot be delayed
fora longerperiod; however, such surgical procedures should beper-
formed in hospitals where 24/7 catheterization laboratories are avail-
able, so as to treat patients immediately in case of perioperative
atherothrombotic events. Independently of the timeframe between
DES implantation and surgery, single anti-platelet therapy (preferably
with aspirin) should be continued.
In patients needing surgery within a few days, current ESC Guide-
lines recommend withholding clopidogrel and ticagrelor for five days
and prasugrel for seven days prior to surgery unless there is a high risk
of thrombosis.74 In contrast, other guidelines recommend using
platelet function tests for optimal timing of surgery, as discussed in
a recent publication.134,135 However, the guidelines do not provide
the ‘ideal’ platelet function assay or a ‘bleeding cut-off’, and more re-
search in this area is needed.
For patients with a very high risk of stent thrombosis, bridging
therapy with intravenous, reversible glycoprotein inhibitors, such as
eptifibatide or tirofiban, should be considered. Cangrelor, the new re-
versible intravenous P2Y12-inhibitor, has been shown to provide ef-
fective platelet inhibition but is not yet available.136 The use of
low-molecular-weight heparin (LMWH) for bridging in these patients
should be avoided. Dual anti-platelet therapy should be resumed as
soon as possible after surgery and, if possible, within 48 hours.
4.2.3 Reversal of anti-platelet therapy
For patients receiving anti-platelet therapy, who have excessive or
life-threatening perioperative bleeding, transfusion of platelets is
recommended.
4.3 Perioperative management in patients
on anticoagulants
Anticoagulant therapy is associated with increased risk of bleeding
during non-cardiac surgery. In some patients, this risk will be out-
weighed by the benefit of anticoagulants and drug therapy should
be maintained or modified, whereas, in patients at low risk of throm-
bosis, anticoagulation therapy should be stopped to minimize bleed-
ing complications.
4.3.1 Vitamin K antagonists
Patients treated with oral anticoagulant therapy using vitamin K antago-
nists (VKAs) are subject toan increasedriskofperi- andpost-procedural
bleeding. If the international normalized ratio (INR) is≤1.5, surgery can
be performed safely; however, in anticoagulated patients with a high risk
of thrombo-embolism—for example, patients with:
† AF with a CHA2DS2-VASc [Cardiac failure, Hypertension, Age
≥75 (Doubled), Diabetes, Stroke (Doubled) – Vascular disease,
Age 65–74 and Sex category (Female)] score of ≥4] or
† mechanical prosthetic heart valves, newly inserted biological pros-
thetic heart valves, or
† mitral valvular repair (within the past 3 months) or
† recent venous thrombo-embolism (within 3 months) or
† thrombophilia,
discontinuationofVKAs ishazardousandthesepatientswillneedbridg-
ing therapy with unfractionated heparin (UFH) or therapeutic-dose
LMWH.69,137 In general, there is better evidence for the efficacy
and safety of LMWH, in comparison with UFH, in bridging to
surgery.69,137 LMWH is usually administered subcutaneously and
weight-adjusted foronce- or twice-daily administrationwithout labora-
tory monitoring. In patients with a high thrombo-embolic risk, thera-
peutic doses of LMWH twice daily are recommended, and
prophylactic once-daily doses in low-risk patients.137 The last dose of
LMWH should be administered no later than 12 hours before the pro-
cedure. Further adjustment of dose is necessary in patients with
Table 6 Pharmacological features of non-vitamin K antagonist oral anticoagulants
b.i.d. ¼ bis in diem (twice daily); Cmax ¼ maximum concentration; CYP3a4 ¼ cytochrome P3a4 enzyme; P gP ¼ platelet glycoprotein; q.d. ¼ quaque die (once daily).
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moderate-to-high kidney function impairment. It is recommended that
VKA treatment be stopped 3–5 days before surgery (depending on the
type of VKA), with daily INR measurements, until ≤1.5 is reached, and
that LMWHor UFHtherapybe startedonedayafterdiscontinuationof
VKA—or later, as soon as the INR is ,2.0.
In patients with mechanical prosthetic heart valves, the evidence in
favour of intravenous UFH is more solid; thus in some centres these
patients are hospitalized and treated with UFH until four hours
before surgery, and treatment with UFH is resumed after surgery
until the INR is within the therapeutic range.69 On the day of the pro-
cedure, the INR should be checked. Consideration should be given to
postponing the procedure if the INR is .1.5. LMWH or UFH is
resumed at the pre-procedural dose 1–2 days after surgery, depend-
ing on the patient’s haemostatic status, but at least 12 hours after the
procedure. VKAs should be resumed on day 1 or 2 after surgery—
depending on adequate haemostasis—with the pre-operative main-
tenance dose plus a boosting dose of 50% for two consecutive days;
the maintenance dose should be administrated thereafter. LMWH or
UFH should be continued until the INR returns to therapeutic levels.
Furthermore, the type of surgical procedure should be taken into
consideration, as the bleeding risk varies considerably and affects
haemostatic control. Procedures with a high risk of serious bleeding
complications are thosewhere compressioncannotbeperformed. In
these cases, discontinuation of oral anticoagulants and bridging
therapy with LMWH are warranted. In patients undergoing surgery
with a low risk of serious bleeding, such as cataract- or minor skin
surgery, no change in oral anticoagulation therapy is needed;
however, it is wise to keep INR levels in the lower therapeutic range.
4.3.2 Non-vitamin K antagonist oral anticoagulants
In patients treated with the non-VKA direct oral anticoagulants
(NOACs) dabigatran (a direct thrombin inhibitor), rivaroxaban, apix-
aban, or edoxaban (all direct factor Xa inhibitors), all of which have a
well-defined ‘on’ and ‘off’ action, ‘bridging’ to surgery is in most cases
unnecessary, due to their short biological half-lives (Table 6).138
An exception to this rule is the patient with high thrombo-embolic
risk, whose surgical intervention is delayed for several days. The
overall recommendation is to stop NOACs for 2–3 times their re-
spective biological half-lives prior to surgery in surgical interventions
with ‘normal’ bleeding risk, and 4–5 times the biological half-lives
before surgery in surgical interventions with high bleeding
risk.139,140 New tests for better quantification of activity levels of
the various NOACs are under development. In general, reduced
kidney function or moderate-to-high increased bleeding risk should
lead to earlier cessation of NOACs. If patients are pre-treated with
dabigatran, which has about an 80% renal excretion rate, the individ-
ual glomerular filtration rate determines the time of its cessation
prior to surgery.139,141 Kidney function is thus essential for tailoring
dabigatran therapy, and earlier cessation is recommended for all
NOACs if the bleeding risk is increased.
Because of the fast ‘on’-effect of NOACs (in comparison with
VKAs), resumption of treatment after surgery should be delayed
for 1–2 (in some cases 3–5) days, until post-surgical bleeding ten-
dency is diminished.
4.3.3 Reversal of anticoagulant therapy
4.3.3.1 Vitamin K antagonists
In patients who are receiving VKAs and who require reversal of the
anticoagulant effect for an urgent surgical procedure, low-dose
(2.5–5.0 mg) intravenous or oral vitamin K is recommended. The
effect of vitamin K on INR will first be apparent after 6–12 hours. If
more immediate reversal of the anticoagulant effect of VKAs is
needed, treatment with fresh-frozen plasma or prothrombin
complex concentrate (PCC), is recommended, in addition to
low-dose intravenous or oral vitamin K.
In patients receiving UFH and requiring reversal of the anticoagu-
lant effect for an urgent surgical procedure, cessation of therapy is
sufficient, because coagulation is usually normal four hours after
cessation. When UFH is given subcutaneously, the anticoagulant
effect is more prolonged. For immediate reversal, the antidote
is protamine sulphate. The dose of protamine sulphate can be
calculated by assessment of the amount of heparin received in the
previous two hours. (http://www.medicines.org.uk/emc/medicine/
10807/spc). The dose of protamine sulphate for reversal of a
heparin infusion is 1 U per 1 U of heparin sodium.
In patients who are receiving LMWHs, the anticoagulant effect
may be reversed within eight hours of the last dose because of
the short half-life. If immediate reversal is required, intravenous
Patient on NOAC presenting
with bleeding
Check haemodynamic status,
basic coagulation tests to assess
for an anticoagulation effect
(e.g. aPTT for dabigatran, etc),
renal function, etc.
















Figure 2 Management of bleeding in patients taking non-vitamin
K antagonist direct oral anticoagulants. From Camm et al. 2012.144
*With dabigatran; aPTT ¼ activated partial thromboplastin time;
NOAC ¼ non-vitamin K antagonist direct oral anticoagulant;
PCC ¼ prothrombin coagulation complex; rFVIIa ¼ activated re-
combinant factor VII.
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protamine sulphate can be used, but anti-Xa activity is never com-
pletely neutralized (maximum 50%).
4.3.3.2 Non-vitamin K antagonist oral anticoagulants
When severe bleeding complications occur under the influence of
NOACs, symptomatic treatment should be initiated (Figure 2)
because of the lack of specific antidotes (these are currently under
development). Preliminary data have shown a potential benefit for
the use of PCC or activated PCC when bleeding occurs under the
direct factor Xa inhibitor rivaroxaban, and is also applicable to apix-
aban142 and dabigatran,143 whereas haemodialysis is an effective
method for eliminating dabigatran from the circulation but does
not help when a direct factor Xa inhibitor has been used (Figure 2).
Recommendations on anti-platelet therapy
Recommendations Classa Levelb Ref.c
It is recommended that aspirin 
be continued for 4 weeks after 
BMS implantation and for 3–12 
months after DES implantation,
unless the risk of life-threatening 
surgical bleeding on aspirin is 
unacceptably high.
I C
Continuation of aspirin, in 
patients previously thus treated,
may be considered in the peri-
operative period, and should be 
based on an individual decision 
that depends on the peri-
operative bleeding risk, weighed 




Discontinuation of aspirin 
therapy, in patients previously 
treated with it, should be 
considered in those in whom 
haemostasis is anticipated to be
difficult to control during 
surgery.
IIa B
Continuation of P2Y12 inhibitor 
treatment should be considered 
for 4 weeks after BMS 
implantation and for 3–12 
months after DES implantation,
unless the risk of life-threatening 
surgical bleeding on this agent is 
unacceptably high.
IIa C
In patients treated with P2Y12
inhibitors, who need to undergo 
surgery, postponing surgery for 
at least 5 days after cessation of 
ticagrelor and clopidogrel—and 
for 7 days in the case of 
prasugrel—if clinically feasible, 
should be considered unless the 
patient is at high risk of an 
ischaemic event.
IIa C





The role of routine, prophylactic, invasive, coronary diagnostic evalu-
ation and revascularization in reducing coronary risk for non-cardiac
surgery remains ill-defined. Indications for pre-operative coronary
angiography and revascularization, in patients with known or sus-
pected IHD who are scheduled for major non-cardiac surgery, are
similar to those in the non-surgical setting.74 Control of myocardial
ischaemia before surgery is recommended whenever non-cardiac
surgery can be safely delayed. There is, however, no indication for
routinely searching for the presence of myocardial (silent) ischaemia
before non-cardiac surgery.
The main reason for pre-operative myocardial revascularization is
the potential prevention of perioperative myocardial ischaemia that
leads to necrosis or electric/haemodynamic instability at the time
of surgery. Coronary pathology underlying fatal perioperative myo-
cardial infarctions revealed that two-thirds of the patients had signifi-
cant left-main or three-vessel disease.145 Most of the patients did not
exhibit plaque fissuring and only one-third had an intracoronary
thrombus. These findings suggest that a substantial proportion of
fatal perioperative myocardial infarctions may have resulted from
low-flow, high-demand ischaemia, owing to the stress of the oper-
ation in the presence of fixed coronary artery stenoses and therefore
amenable to revascularization. In patients who underwent coronary
angiography before vascular surgery, a number of non-fatal peri-
operative myocardial infarctions occurred as a consequence of
plaque rupture in arteries without high-grade stenosis. These
results are not surprising, considering the extreme and complex
stress situations associated with surgery—such as trauma, inflamma-
tion, anaesthesia, intubation, pain, hypothermia, bleeding, anaemia,
fasting, and hypercoagulability—which may induce multiple and
complex pathophysiological responses.146
The Coronary Artery Surgery Study (CASS) database includes
almost 25 000 patients with CAD, initially allocated to either coron-
ary artery bypass graft (CABG) surgery or medical management,
with a follow-up of .10 years, and 3368 underwent non-cardiac
surgery during follow-up.147 A retrospective analysis of this popu-
lation suggested that vascular, abdominal, and major head and
neck surgeries were associated with a higher risk of perioperative
myocardial infarction and death in the presence of non-
revascularized CAD. Furthermore, the study showed that patients
whowere clinically stable in theyears after CABG had a reduced risk
of cardiac complications in the event that they required non-cardiac
surgery. This protective effect of previous coronary revasculariza-
tion was more pronounced in patients with triple-vessel CAD
and/or depressed LV function, as well as in those undergoing high-
risk surgery, and lasted for at least six years; however, the study was
performed at a time when medical therapy did not meet current
standards. It can be concluded that asymptomatic patients who
underwent CABG within the previous six years are relatively pro-
tected from myocardial infarction complicating non-cardiac
surgery and may undergo non-cardiac surgery without routine pre-
operative stress testing. This may not be the recommendation for
patients with decreased LV function, as illustrated in a small
cohort of 211 patients who underwent non-cardiac surgery
within one year of CABG and in whom perioperative predictors
for mortality at one year were: LV ejection fraction (LVEF)
,45% (P , 0.001), elevated right ventricular systolic pressure
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(P ¼ 0.03), emergency operation (OR 6.8), need for dialysis (P ¼
0.02) or ventilator support (P ¼ 0.03).148
As mentioned above, patients who have had a previous PCI may be
athigher riskof cardiac events duringorafter subsequentnon-cardiac
surgery, particularly in cases of unplannedorurgent surgery following
coronary stenting. It is therefore preferable, whenever possible, to
postpone elective surgery until 12 months after DES implantation.149
However, recent data have suggested that, beyond six months fol-
lowing newer-generation DES implantation—and, for some specific
DES devices, beyond three months of DES implantation—the peri-
operative cardiac event rates may be acceptable.126,132,150 Independ-
ently of the interval between DES implantation and surgery, aspirin
should be continued and, in cardiac-stable/asymptomatic patients
with recent myocardial infarction treated with stenting, the timing
of non-cardiac, non-urgent surgery will in part be dictated by the
type of stent implanted.
Recommendations on the timing of non-cardiac surgery
in cardiac-stable/asymptomatic patients with previous
revascularization
Recommendations Classa Levelb Ref. c
It is recommended that, except for 
high-risk patients, asymptomatic 
patients who have undergone CABG 
in the past 6 years be sent for non-
urgent, non-cardiac surgery without 
angiographic evaluation.d
I B 147,148
Consideration should be given to 
performing non-urgent, non-cardiac 
surgery in patients with recent BMS 
implantation after a minimum of 4 
weeks and ideally 3 months following 
the intervention.d
IIa B 129
Consideration should be given to 
performing non-urgent, non-cardiac 
surgery in patients who have had 
recent DES implantation no sooner 
than 12 months following the 
intervention. This delay may be 
reduced to 6 months for the new-
generation DES.d
IIa B 149,150
In patients who have had recent 
balloon angioplasty, surgeons should 
consider postponing non-cardiac 
surgery until at least 2 weeks after 
the intervention.
IIa B 127,151
BMS ¼ bare-metal stent; CABG ¼ coronary artery bypass graft surgery;




dAspirin to be continued throughout perioperative period.
4.4.1 Prophylactic revascularization in patients with
asymptomatic or stable ischaemic heart disease
Giving clear recommendations on prophylactic revascularization in
patients with asymptomatic or stable IHD is challenging, as most of
the data are derived from retrospective studies and registries.
The Coronary Artery Revascularization Prophylaxis (CARP)
trial compared optimal medical therapy with revascularization
(CABG or PCI) in patients with stable IHD before major vascular
surgery.152 Of 5859 patients screened at 18 centres of the United
States Department of Veterans Affairs, 510 patients were enrolled
in a randomized trial. Patients were included, based on increased
risk for perioperative cardiac complications, as assessed by the con-
sultant cardiologist on the basis of a combination of cardiovascular
risk factors and the detection of ischaemia on non-invasive testing;
28% of the study patients had three or more clinical risk factors
and 49% had two or more variables as defined by the revised
cardiac risk index. There was no difference in either mortality or peri-
operative myocardial infarction at 2.7 years after commencement of
the trial. The results of the CARP study indicated that systematic
prophylactic revascularization before vascular surgery does not
improve clinical outcomes in stable patients.
A second prospective, randomized trial included 208 patients,
selected on the basis of a revised cardiac risk index, who were
scheduled for major vascular surgery.153 Patients were randomly
allocated to either a ‘selective strategy’ in which coronary angiog-
raphy was performed, based on the results of non-invasive tests,
or to a ‘systematic strategy’, in which patients routinely underwent
a pre-operative coronary angiography. While the rate of myocardial
revascularization was higher in the systematic strategy group (58.1%
vs. 40.1%), the perioperative, in-hospital, adverse cardiac event rate
(defined as mortality, non-fatal myocardial infarction, cerebrovas-
cular accident, heart failure, and need for new cardiac revasculariza-
tion procedures), although higher in the selective strategy group,
was not significantly different from that in the systematic strategy
group (11.7% vs. 4.8%; P ¼ 0.1). In contrast, the long-term
outcome (after 58+ 17 months) in terms of survival and freedom
from cardiac events was significantly better in the systematic strat-
egy group.
A recent randomized, prospective, controlled trial, focussing on a
particular homogeneous subset of non-cardiac surgical interventions
(CEA), examined the value of pre-operative coronary angiography
and stenting in 426 patients without history of CAD or cardiac symp-
toms and with normal cardiac ultrasound and electrocardiography
results. The patients were randomized to pre-operative coronary
angiography and—if needed—revascularization, or to no coronary
angiography. The primary combined endpoint was the incidence of
any post-operative myocardial ischaemic events combined with the
incidence of complications of coronary angiography and stenting.
In the angiography group, 68 patients (31%) experienced a significant
coronary artery stenosis; 66 of these patients underwent stenting
(87% with a DES) and two underwent CABG, with no post-operative
events. In the non-angiography group, nine ischaemic events
were observed (4.2%; P ¼ 0.01). In this particular group of patients,
the results suggest a short-term benefit of systematic coronary
angiography.76
Covering 3949 patients enrolled in 10 studies between the years
1996 and 2006 (nine observational and the CARP randomized
trial), a meta-analysis that addressed the value of pre-operative cor-
onary revascularization before non-cardiac surgery revealed no sig-
nificant difference between coronary revascularization and medical
management groups, in terms of post-operative mortality and
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myocardial infarction (OR 0.85; 95% CI 0.48–1.50 and OR 0.95;
95% CI 0.44–2.08, respectively).154 There were no long-term
outcome benefits associated with prophylactic coronary revascu-
larization (OR 0.81; 95% CI 0.40–1.63 for long-term mortality
and OR 1.65; 95% CI 0.70–3.86 for late adverse cardiac events);
thus, in asymptomatic patients or those with stable CAD, prophy-
lactic coronary angiography—and, if needed, revascularization
before non-cardiac surgery—does not confer any beneficial
effects as compared with optimal medical management in terms
of perioperative mortality, myocardial infarction, long-term mortal-
ity, and adverse cardiac events.
Successful performance of a vascular procedure, without pro-
phylactic revascularization, in a stable coronary patient, does
not imply that the patient wouldnot require subsequent revasculariza-
tion. Despite the lack of extensive scientific data, myocardial revascu-
larization may be recommended in patients presenting with persistent
signsofextensive ischaemiabeforeelectivenon-cardiac surgerysimilar
to non-surgical settings recommended by the ESC Guidelines.56
4.4.2 Type of prophylactic revascularization in patients
with stable ischaemic heart disease
Occasionally, patients with stable IHD may require elective surgery,
which may be postponed for several months and up to a year. There
are no solid data to guide a revascularization strategy in such a case.
It seems reasonable to propose a cardiovascular work-up according
to the ESC Guidelines on stable angina pectoris.56 Revascularization
should be considered, in order to improve symptoms and prognosis
in patients with obstructive CAD. All patients considered for revas-
cularization should receive optimal medical treatment. The timing
of revascularization is critical and depends on the clinical presenta-
tion: stable vs. ACS. The type of revascularization, CABG vs. PCI,
depends on the extent of CAD and technical feasibility and is dis-
cussed in detail in the ESC Guidelines on myocardial revasculariza-
tion,74 of which a new edition will be published in 2014.
Percutaneous coronary intervention should be performed to
improve symptoms in stable symptomatic patients with single or
multi-vessel disease, in whom intervention is technically appropri-
ate and procedural risk does not outweigh the potential benefit.
The choice between PCI and CABG, often a matter of debate,
will depend on several factors: according to the 5-year results of
the Synergy between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery (SYNTAX) trial, CABG should
remain the standard of care for patients with complex lesions
(high or intermediate SYNTAX scores). For patients with less-
complex disease (low SYNTAX scores) or left-main coronary
disease (low or intermediate SYNTAX scores) PCI is an acceptable
alternative.155 In the presence of minimal symptoms or their
absence, these patients may be treated medically. If PCI is per-
formed before non-cardiac surgery, according to the previous
edition of these Guidelines, BMS is advocated in order not to
delay the surgery; however, if the data from recent trials evaluating
newer DES devices are confirmed, this recommendation may no
longer be valid and certain new-generation DES may be used in
low-risk patients requiring early non-cardiac surgery.132 If non-
cardiac surgery cannot be postponed, CABG should be favoured
over BMS-based PCI in patients with a higher risk of re-stenosis
(small diameter vessel; long lesions; multiple stents required; left-
main trunk lesions) unless the need for a shorter duration of
DAPT, using new-generation DES devices, is confirmed.
Recommendations for prophylactic revascularization in
stable/asymptomatic patients
Recommendations Classa Levelb Ref. c
Performance of myocardial 
revascularization is recommended 
according to the applicable 
guidelines for management in stable 
coronary artery disease.
I B 56
Late revascularization after 
successful non-cardiac surgery 
should be considered, in 
accordance with ESC Guidelines on 
stable coronary artery disease.
I C
Prophylactic myocardial 
revascularization before high-risk 
surgery may be considered, 
depending on the extent of a stress-
induced perfusion defect.
IIb B 147
Routine prophylactic myocardial 
revascularization before low- and 
intermediate-risk surgery in patients 
with proven IHD is not 
recommended.
III B 152




4.4.3 Revascularization in patients with non-ST-elevation
acute coronary syndrome
No trial has yet investigated the role of prophylactic revasculariza-
tion in patients with NSTE-ACS requiring non-cardiac surgery;
therefore, if the clinical condition requiring non-cardiac surgery is
not life-threatening, priority should be given to the management
of NSTE-ACS. In such cases, the 2011 ESC Guidelines on the
management of NSTE-ACS apply.73 With regard to the type of
coronary revascularization employed in patients later requiring
non-cardiac surgery, most undergo PCI. In the rare scenario of
NSTE-ACS linked with the need for subsequent early non-cardiac
surgery, at the time of PCI, preference should be given either to
BMS, in order to avoid delaying surgery beyond 1 and preferably
3 months, or to new-generation DES if data from recent trials
confirm non-inferiority.156,157 In rare cases, balloon angioplasty
alone may be a reasonable strategy if a good acute result is expected,
because aspirin—rather than dual anti-platelet therapy—may be
sufficient.156
The value of coronary revascularization for NSTE-ACS, in patients
who later require non-cardiac surgery, has been addressed in a retro-
spective analysis covering 16 478 patients who, between 1999 and
2004, had a myocardial infarction and underwent hip surgery, chole-
cystectomy, bowel resection, elective AAA repair, or lower extrem-
ity amputation in a period of up to three years following the
myocardial infarction. This study showed that patients who were
revascularized before surgery had an approximately 50% lower
rate of re-infarction (5.1% vs. 10.0%; P , 0.001) as well as 30-day
(5.2% vs. 11.3%; P , 0.001) and 1-year mortality (18.3% vs. 35.8%;
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P, 0.001) compared with those who were not revascularized. This
large sample, representing real-world practice, suggests that patients
with a recent myocardial infarction can benefit from pre-operative
revascularization.158
Recommendations on routine myocardial
revascularization in patients with NSTE-ACS
Recommendations Classa Levelb Ref. c
If non-cardiac surgery can 
safely be postponed, it is 
recommended that patients 
should be diagnosed and 





In the unlikely combination of 
a life-threatening clinical 
condition requiring urgent 
non-cardiac surgery and 
revascularization for NSTE-
ACS, the expert team should 
discuss, case by case, the 
priority of surgery.
IIa C 133
In patients who have 
undergone non-cardiac 
surgery, aggressive medical 
treatment and myocardial 
revascularization according to 
the guidelines on NSTE-ACS 
are recommended following 
surgery.
I B 73
If PCI is indicated before semi-
urgent surgery, the use of 
new-generation DES, BMS or 
even balloon angioplasty is 
recommended.
I B 151,156
ACS ¼ acute coronary syndromes; BMS ¼ bare-metal stent; DES ¼ drug-eluting






Several specific diseases merit special consideration in terms of
cardiovascular pre-operative assessment.
5.1 Chronic heart failure
The diagnosis of heart failure requires the presence of symptoms and
signs typical of heart failure and, in addition, evidence of reduced LV
function [heart failure with reduced LVEF (HF-REF)] or a non-dilated
left ventricle with normal or nearly normal systolic function and rele-
vant structural disease and/or diastolic dysfunction [heart failurewith
preserved LVEF (HF-PEF)].159 The prevalence of heart failure in
developed countries is 1–2%, but rises to ≥10% among persons
≥70 years of age.160
Heart failure is awell-recognized factor forperioperative andpost-
operative cardiac events and is an important predictor in several
commonly used risk scores.41– 43,161 –164 In a large registry analysis
of 160 000 Medicare procedures on patients aged ≥65 years, heart
failure was present in 18% and was associated with a 63% increased
risk of operative mortality and a 51% greater risk of 30-day all-cause
re-admission, compared with the CAD group or patient group
without heart failure.163 A reduced LVEF of ≤35% was found to be
a strong predictorof post-operative cardiac events followingvascular
surgery.165 The prognostic impact of HF-PEF on perioperative mor-
bidity andmortality is not well defined.One study foundnosignificant
differences in events between controlled HF-PEF and HF-REF
patients undergoing non-cardiac surgery,166 whereas another
found that only those with severely depressed LVEF (,30%) had
increased perioperative event rates, compared with a group with
moderate (LVEF 30–40%) or mildly (LVEF .40, ,50%) reduced
LV function.167 Compared with HF-REF patients, HF-PEF patients
tend to be older, female, more likely to have hypertension and AF,
and less likely to have CAD; generally, their prognoses are also
better.168 In the absence of evidence-based studies, the similar peri-
operative management can be recommended in patients with HF-PEF
as in patients with HF-REF, with emphasis also on parameters besides
LVEF, such as general clinical status, evidence of volume overload, and
increased levels of natriuretic peptides.
Transthoracic echocardiography (TTE) is a key element in the pre-
operative assessment of patients with known or suspected heart
failure. LVEF, as well as LV and atrial volumes should be measured
with bi-planar or three-dimensional echocardiography.169 Assess-
ments of valve function and diastolic function (such as E/e’ ratio)
are likewise of major importance,170 as is evaluation of inferior vena
cava diameter for the determination of volume status and right
atrial pressure. Deformation imaging with strain analysis may reveal
dysfunction that is not apparent using traditional methods.170 The in-
formation on cardiac structure and function obtained by TTE pro-
vides important prognostic information before non-cardiac
surgery.59,171 Thus, routine pre-operative echocardiography should
be considered in high-risk surgical populations; however, routine
echocardiography is not indicated in every cardiac patient. In a
large Canadian cohort study, pre-operative echocardiography was
not associated with improved survival or shorter hospital stay follow-
ing major non-cardiac surgery.172 In emergency non-cardiac surgery,
a pre-operative-focussed TTE examination may significantly alter
diagnosis and management.173 In patients with a poor echocardio-
graphic window, CMR imaging is an excellent method for the evalu-
ation of both cardiac structure and function.174
The pre-operative levels of natriuretic peptides (BNP or NT
proBNP) are strongly correlated to the prognosis of heart failure
and to perioperative and post-operative morbidity and mortal-
ity.3,175,176 Compared with a pre-operative natriuretic-peptide meas-
urement alone, additional post-operative natriuretic-peptide
measurement enhanced risk stratification for the composite out-
comes of death or non-fatal myocardial infarction at 30 days
and ≥ 180 days after non-cardiac surgery.55 Thus, the assessment
of natriuretic peptides should form part of a routine pre-operative
evaluation when cardiac dysfunction is known or suspected.
The best assessment of a patient’s overall functional capacity is
achieved by performing a cardiopulmonary exercise test (CPX/
CPET).177 Both the cardiac and pulmonary reserve and their inter-
action can then be evaluated; this is far more accurate than judging
the capacity by interview alone. An anaerobic threshold of
,11 mL O2/kg/min has been used as a marker of increased risk.
177
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Two review papers have assessed the role of CPX as a pre-operative
evaluation tool.178,179 Meta-analyses are difficult, due to heterogen-
eity in methodology and outcome measures. There are no ’blinded’
studies and the CPX results may influence the decision on whether
to operate on a patient with a potentially serious disease and progno-
sis. One of the above papers concludes that paucity of robust data
precludes routine adoption of CPX in risk-stratifying patients under-
going major vascular surgery,178 while the other reports that peak
oxygen consumption—and possibly anaerobic threshold—are
valid predictors of perioperative morbidity and mortality in patients
undergoing non-cardiopulmonary thoraco-abdominal surgery.179
The currentESC Guidelinesonacute and chronic heart failure give a
strong recommendation for the use of optimal tolerated doses of ACE
inhibitors (or ARBs in the case of ACE intolerance), beta-blockers, and
aldosterone antagonists as primary treatment strategies in patients
with HF-REF, to reduce morbidity and mortality.159 Digitalis is a
third-level drug to be considered in patients treated optimally with
recommended drugs.159 All patients with heart failure, who are sched-
uled for non-cardiac surgery, should be treated optimally according to
these recommendations. Furthermore, HF-REF patients with LVEF
≤35%and leftbundlebranchblockwithQRS≥120 msshouldbeeval-
uated with respect to cardiac resynchronization therapy (CRT) or
CRT-defibrillator (CRT-D) therapybeforemajor surgery.159 Diuretics
are recommended in heart failure patients who have signs or symp-
toms of congestion (see section 4.1.7).159
In patients with newly diagnosed severe systolic heart failure, it is
recommended that non-urgent surgery be deferred for at least
three months to allow a new medical therapy and/or intervention
ample time to improve LV function and LV remodelling.164 Rapid pre-
operative initiation of high doses of beta-blockers78 and/or ACEIs,
without adequate time for dose titration, is not recommended.
Patients with heart failure should preferably be euvolemic before
elective surgery, with stable blood pressure and optimal end-organ
perfusion.
Although continuation of ACEIs/ARBs until the day of surgery has
been associated with an increased incidence of hypotension,180 it is
in general recommended that all heart-failure medications, such as
ACE inhibitors, ARBs, and beta-blockers, be continued and that the
patient’s haemodynamic status be carefully monitored and give
appropriate volume replacement when necessary. In patients con-
sidered susceptible to hypotension, transient discontinuation
the day before surgery may be considered. Evening dosage of
ACEIs/ARBs the day before surgery—and not on the morning of
surgery—may be considered in order to avoid hypotension,
whereas beta-blockade should be continued if possible. Heart
failure medications should be re-instituted post-operatively, as
soon as clinical conditions allow. Consider also the possibility of
giving the medications via nasogastric tube or bioequivalent intra-
venous dose. Regarding patients with LV-assist devices, who are
scheduled for non-cardiac surgery, they should be evaluated
pre-operatively by the centre responsible for implantation and
follow-up. Patients with HF-PEF have an increased stiffness of the
left ventricle and are susceptible to pulmonary oedema with
fluid overload. Adequate perioperative monitoring, attention to
volume status, control of afterload, and adequate diuretic treatment
are important considerations for these patients.
Post-operative heart failure may pose diagnostic challenges,
as it often presents atypically and may have a different aetiology
from the non-surgical setting. The evaluation should include physical
examination, ECG, serial biomarker measurements for both
ischaemic myocardial damage and natriuretic peptides, X-ray, and
echocardiography. Special attention should be given to the patient’s
volume status since high-volume infusion is often needed in the
intra-operative and immediate post-operative setting. In the period
after surgery, fluids given during the operation may be mobilized,
causing hypervolaemia and pulmonary congestion. Careful attention
to fluid balance is therefore essential.
Once the aetiology of post-operative heart failure has been diag-
nosed, treatment is similar to the non-surgical setting. Patients who
develop heart failure have a significantly increased risk of hospital re-
admission after surgical procedures, confirming the need for careful
discharge planning and close follow-up, ideally using a multidisciplin-
ary approach.159
Recommendations on heart failure
Recommendations Classa Levelb Ref. c
It is recommended that patients with 
established or suspected heart failure, 
and who are scheduled for non-
cardiac intermediate or high-risk 
surgery, undergo evaluation of LV 
function with transthoracic 
echocardiography and/or assessment 
of natriuretic peptides, unless they 




It is recommended that patients with 
established heart failure, who are
scheduled for intermediate or high-
risk non-cardiac surgery, be 
therapeutically optimized as 
necessary, using beta-blockers, ACEIs
or ARBs, and mineralocorticoid 
antagonists and diuretics, according to 
ESC Guidelines for heart failure 
treatment.
I A 159
In patients with newly diagnosed heart 
failure, it is recommended that 
intermediate- or high-risk surgery be 
deferred, preferably for at least 3 
months after initiation of heart failure 
therapy, to allow time for therapy up-
titration and possible improvement of 
LV function. 
I C 164
It is recommended that beta blockade
be continued in heart failure patients 
throughout the peri-operative period, 
whereas ACEIs/ARBs may be omitted 
on the morning of surgery, taking into 
consideration the patient’s blood 
pressure. If ACEIs/ARBs are given, it is 
important to carefully monitor the
patient's haemodynamic status and 
give appropriate volume replacement 
when necessary.
I C
Unless there is adequate time for 
dose-titration, initiation of high-dose 
beta-blockade before non-cardiac 
surgery in patients with heart failure is 
not recommended.
III B
ACEI ¼ angiotensin converting enzyme inhibitor; ARB ¼ angiotensin receptor











In general, the presence of arterial hypertension is a risk factor, but
not a very strong independent one for cardiovascular complications
in non-cardiac surgery. In a systematic review and meta-analysis of
30 observational studies, pre-operative hypertension was asso-
ciated with a 35% increase in cardiovascular complications;181
however, uncontrolled blood pressure is one of the commonest
causes of deferred operation.182 When raised blood pressure is dis-
covered in a pre-operative evaluation, it is advisable to search for
target organ damage and evidence of associated cardiovascular
pathology (ECG, renal function parameters, and evidence of
heart failure), and to initiate therapy to lower the blood pressure
to an appropriate level; this is particularly important for those
with concomitant risk factors. It is also important to validate the
diagnosis by multiple measurements, considering ambulatory mon-
itoring if necessary.183
During the induction of anaesthesia, sympathetic activation can
cause an increase in blood pressure of 20–30 mm Hg and a heart
rate increase of 15–20 bpm in normotensive individuals.184 This
response may be more pronounced in patients with untreated
hypertension. As the period of anaesthesia progresses, patients
with pre-existing hypertension are more likely to experience lability
of intra-operative blood pressure, which may lead to myocardial
ischaemia. Avoiding excessive peaks in pressure is important but
the hypertensive patient may also be unstable, and profound
hypotension—especially when associated with baroreflex-mediated
tachycardia—may be equally detrimental. In a study on hypertensive
and diabetic patients undergoing non-cardiac surgery, a decrease in
blood pressure of .20 mm Hg for .1 hour was found to be a risk
factor for complications.185 It is recommended that perioperative
blood pressure be kept at 70–100% of baseline, avoiding excessive
tachycardia. Post-surgical elevation of blood pressure is frequently
brought about by anxiety and pain after awakening, and may return
to normal after treating these factors.
Common reasons for delaying surgery in patients with hyperten-
sion are poorly controlled blood pressure of grade 3 (systolic
blood pressure ≥180 mm Hg and/or diastolic blood pressure
≥110 mm Hg), discoveryof end-organdamage thathasnotprevious-
ly been evaluated or treated, or suspicion of secondary hypertension
without properly documented aetiology. In patients with grade 1 or 2
hypertension (systolic blood pressure,180 mm Hg; diastolic blood
pressure,110 mm Hg) there is no evidence of benefit from delaying
surgery to optimize therapy.182 In such cases, antihypertensive med-
ications should be continued during the perioperative period. In
patients with grade 3 hypertension, the potential benefits of delaying
surgery to optimize the pharmacological therapy should be weighed
against the risk of delaying the procedure. In a randomized study,
when compared with deferred surgery, immediate blood pressure
reduction with nifedipine was associated with similar complication
rates but a shorter hospital stay.186
There is no clear evidence favouring one mode of antihypertensive
therapy over another in patients undergoing non-cardiac surgery.
Patients with arterial hypertension should be managed according
to existing ESC Guidelines.183 For more information on periopera-
tive use of hypertensive medications, see section 4.1.
Recommendations on arterial hypertension
Recommendations Classa Levelb Ref. c
It is recommended that patients with 
a new diagnosis of hypertension pre-
operatively be screened for end-organ 
damage and cardiovascular risk 
factors.
I C
Large peri-operative fluctuations in 
blood pressure in hypertensive
patients should be avoided.
IIa B 187
Clinicians may consider not deferring
non-cardiac surgery in patients with 
grade 1 or 2 hypertension (systolic 
blood pressure <180 mm Hg; diastolic 





5.3 Valvular heart disease
Patients with VHD are at increased risk of perioperative cardiovascu-
lar complications during non-cardiac surgery.69 The risk is highly vari-
able, according to the type and severity of VHD and the type of
non-cardiac surgery.
5.3.1 Patient evaluation
Echocardiography should be performed on any prospective non-
cardiac surgery patient with known or suspected VHD, in order to
assess its severity and consequences. This is particularly relevant in
the presence of a cardiac murmur. In the presence of severe VHD,
it is recommended that a clinical and echocardiographic evaluation
be performed and, if necessary, treated before non-cardiac surgery.
As for the general evaluation of a patient with VHD, the key issues
are to assess the severity of VHD, the symptoms and their relation-
ship to VHD, and the estimated risks of valvular intervention and of
cardiac complications according to the type of non-cardiac surgery.
The usual classification of non-cardiac surgery, using the three risk
groups defined in Table 3, should also be used in patients with VHD.
5.3.2 Aortic stenosis
Aortic stenosis is the most common VHD in Europe, particularly
among the elderly. Severe aortic stenosis is defined according to an
integrative approach taking into account valve area (,1.0 cm2 or
0.6 cm2/m2 body surface area, except in obese patients), and flow-
dependent indices (maximum jet velocity 4 m/sec and mean aortic
pressure gradient ≥40 mm Hg).
Severe aortic stenosis constitutes a well-established risk factor for
perioperative mortality and myocardial infarction. In the case of
urgent non-cardiac surgery in patients with severe aortic stenosis,
such procedures should be performed under more invasive haemo-
dynamic monitoring, avoiding rapid changes in volume status and
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heart rhythm as far as possible. In the case of elective non-cardiac
surgery, the presence of symptoms is essential for decision-making.69
In symptomatic patients, aortic valve replacement should be con-
sidered before elective surgery.69 In patients who are not candidates
for valve replacement, due either to high risks associated with serious
comorbidities or refusal to undergo the operation, non-cardiac
surgery should be performed only if is essential. In patients at high
risk or contra-indicated for aortic valve replacement, balloon aortic
valvuloplasty or, preferably, transcatheter aortic valve implantation
(TAVI) may be a reasonable therapeutic option before surgery.69
The choice between balloon aortic valvuloplasty and TAVI should
take into account the impact of non-cardiac disease on life expect-
ancy and the degree of urgency of the non-cardiac surgery.
In asymptomatic patients, non-cardiac surgeryof lowto intermedi-
ate risk can be performed safely;188 If possible, the absence of symp-
toms should be confirmed by exercise testing. If high-risk surgery is
planned, further clinical assessment is necessary to assess the risk
of aortic valve replacement. In those at high risk for aortic valve re-
placement, elective surgery under more invasive haemodynamic
monitoring should be performed only if strictly necessary. In the
remaining patients, aortic valve replacement should be considered
as the initial procedure.69
5.3.3 Mitral stenosis
Non-cardiac surgery can be performed with relatively low levels of
risk in patients with non-significant mitral stenosis (valve area
.1.5 cm2) and in asymptomatic patients with significant mitral sten-
osis (valve area ,1.5 cm2) and systolic pulmonary artery pressure
,50 mm Hg. Pre-operative surgical correction of mitral stenosis in
these patients is not indicated. Control of heart rate is essential to
avoid tachycardia, which may cause pulmonary oedema. Attentive
control of fluid overload is also important. Development of AF may
cause serious clinical deterioration. With the high risk of embolism,
anticoagulation control is important.69,189 In asymptomatic patients
with significant mitral stenosis and systolic pulmonary artery pres-
sure .50 mm Hg, and in symptomatic patients, the risk related to
the non-cardiac procedure is significantly higher, and these patients
may benefit from percutaneous mitral commissurotomy (or open
surgical repair) particularly before high-risk surgery.69,189
5.3.4 Primary aortic regurgitation and mitral regurgitation
Non-significant aortic regurgitation and mitral regurgitation do not
independently increase the risk of cardiovascular complications
during non-cardiac surgery. In asymptomatic patients with severe
aortic or mitral regurgitation and preserved LV function, non-cardiac
surgery can be performed without additional risk. Symptomatic
patients—and those who are asymptomatic with severely impaired
LVEF (,30%)—are at high risk of cardiovascular complications,
and non-cardiac surgery should be performed only if necessary.69
Patients with severe aortic or mitral regurgitation and heart failure
may benefit from optimization of pharmacological therapy to
produce maximal haemodynamic stabilization before undergoing
high-risk surgery (see section 5.1).
5.3.5 Secondary mitral regurgitation
Secondary mitral regurgitation is due to LV remodelling that causes a
distortion of the subvalvular apparatus on a structurally normal valve.
In the case of non-cardiac surgery, these patients should undergo
perioperative evaluation and management according to the recom-
mendations for LV systolic dysfunction and, if secondary mitral
regurgitation is due to IHD, those for IHD. Because secondary
mitral regurgitation is variable according to loading conditions, par-
ticular attention should be paid to the assessment of volume status
and heart rhythm during the perioperative period.
5.3.6 Patients with prosthetic valve(s)
Patients whohaveundergoneprevious surgical correctionofVHDand
have a prosthetic valve can undergo non-cardiac surgery without add-
itional risk, provided that there is no evidence of valve or ventricular
dysfunction. In current practice, the main problem is the need for a
modification of the anticoagulation regimen in patients in the peri-
operative period, with oral anticoagulants being temporarily replaced
by UFH or LMWH at therapeutic doses (see section 4.3).
5.3.7 Prophylaxis of infective endocarditis
Indications for antibiotic prophylaxis are limited to high-risk patients
undergoing dental care; however, non-specific prophylaxis remains
recommended in all patients at intermediate or high risk of infective
endocarditis. This is of particular importance in the field of non-
cardiac surgery, given the increasing burden of healthcare-related in-
fectiveendocarditis. Prophylaxis of infectiveendocarditis is discussed
in detail in specific ESC guidelines.190
Recommendations on VHD




recommended in all 
patients with known or 
suspected VHD, who are 
scheduled for elective 
intermediate or high-risk 
non-cardiac surgery.
I C
Aortic valve replacement 
is recommended in 
symptomatic patients with 
severe aortic stenosis,
who are scheduled for 
elective non-cardiac 
surgery, provided that
they are not at high risk 
of an adverse outcome 
from for valvular surgery.
I B 69
Aortic valve replacement 
should be considered in 
asymptomatic patients 
with severe aortic 
stenosis, who are 
scheduled for elective 
high-risk non-cardiac 
surgery, provided that
they are not at high risk 
of an adverse outcome 
from for valvular surgery.
IIa C
Elective low or 
intermediate-risk non-
cardiac surgery should be 
considered in 
asymptomatic patients 
with severe aortic 
stenosis if there has been 
no previous intervention 
on the aortic valve.
IIa C
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In symptomatic patients 
with severe aortic 
stenosis who are 
scheduled for elective 
non-cardiac surgery, TAVI 
or balloon aortic 
valvuloplasty should be 
considered by the expert 
team if they are at high 
risk of an adverse 




surgery should be 
considered in patients
with severe valvular 
regurgitation, who do not 





be considered in patients 
with severe mitral 
stenosis, who have 
symptoms of pulmonary 
hypertension and are 
scheduled for elective 
intermediate- or high-risk 
non-cardiac surgery.
IIa C
Recommendations Classa Levelb Ref. c






Cardiac arrhythmias are a significant cause of morbidity and mortality
in the perioperative period. Although the mechanisms for
arrhythmias in patients with structural heart disease are reasonably
well-defined, the modulating influence of transient physiological
imbalance in patients undergoing surgery is less certain. Before
surgery, patients with a history of arrhythmias should be reviewed
by a cardiologist. Arrhythmias such as AF and ventricular tachycardia
often indicate underlying structural heart disease; therefore the
discovery of such pre-operative arrhythmias should lead to evalu-
ation, including echocardiography, before surgery.*
5.4.1 New-onset ventricular arrhythmias in the
pre-operative period
Ventricular arrhythmias, including ventricular premature beats
(VPBs) and ventricular tachycardia (VT) are particularly common
in high-risk patients. Monomorphic VT may result from myocardial
scarring, and polymorphic VT is a common result of acute myo-
cardial ischaemia. Pre-operative detection of these arrhythmias
should therefore lead to evaluation including methods such as
echocardiography, coronary angiography (with revascularization)
and, in selected cases, invasive electrophysiological study, as
appropriate.
Treatment steps for VPBs include identifying and correcting the re-
versible causes (e.g. hypoxia, hypokalemia and hypomagnesaemia).
There is no evidence that VPBs or non-sustained VTs alone are asso-
ciated with a worse prognosis or that suppressive therapy is beneficial.
The American College of Cardiology/American Heart Asso-
ciation/ESC Guidelines for management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death recommend
that, regardless of the cause, sustained monomorphic VT with
haemodynamic compromise must be treated promptly with electric
cardioversion. Intravenous amiodarone can be used for initial treat-
ment of patients with stable sustained monomorphic VT, to
prevent recurrences.191
Immediate defibrillation is required to terminate ventricular
fibrillation and sustained polymorphic VT. Beta-blockers are useful
in patients with recurrent sustained polymorphic VT, especially if is-
chaemia is suspected or cannot be excluded. Amiodarone is reason-
able for patients with recurrent sustained polymorphic VT in the
absence of long QT syndrome.191 Torsades de pointes (TdP) may
occur and the withdrawal of any offending drugs and correction of
electrolyte abnormalities are recommended. Management with mag-
nesium sulphate should be considered for patients with TdP and long
QT syndrome.192 Beta-blockade, combined with temporary pacing,
is suggested in patients with TdPand sinus bradycardia. Isoproterenol
is recommended in patients with recurrent, pause-dependent TdP,
who do not have congenital long QT syndrome.191
If the diagnosis is unclear, wide-QRS tachycardia should be pre-
sumed to be VT until proven otherwise. Calcium channel blockers,
such as verapamil and diltiazem, should not be used in patients to ter-
minatewide-QRS-complex tachycardia of unknown origin, especially
in patients with a history of myocardial dysfunction.191
5.4.2 Management of supraventricular arrhythmias and
atrial fibrillation in the pre-operative period
Supraventricular arrhythmias and AF are more common than ven-
tricular arrhythmias in the perioperative period. The aetiology of
these arrhythmias is multifactorial. Sympathetic activity, as the
primary autonomic mechanism, can be responsible for triggering AF.
While initiating specific drug therapy, possible aggravating factors
such as respiratory failure or electrolyte imbalance should also be
corrected. No medication is recommended to suppress supraventri-
cular prematurebeats.Vagalmanoeuvresmay terminateSVT in some
cases; theyusually respond well to treatment with adenosine. In cases
with incessant or commonly recurring SVT in the perioperative
setting, where prophylactic treatment is needed, beta-blockers,
calcium channel blockers, or amiodarone treatment can be used.
In rare cases (and taking into account the urgency and nature of
planned surgery), pre-operative catheter ablation of the arrhythmia
substrate may be considered, e.g. for patients with Wolff-Parkinson-
White syndrome and pre-excited AF.
Theobjective in managingperioperativeAF is usually ventricular rate
control. As recommended in the ESC Guidelines for management of
AF, beta-blockers and calcium channel blockers (verapamil, diltiazem)
are the drugs of choice for rate control.144 Amiodarone can be used
asafirst-linedruginpatientswithheartfailure,sincedigoxin is frequently
ineffective in high adrenergic states such as surgery. Beta-blockers
have been shown to accelerate the conversion of AF to sinus rhythm
in the intensivecareunit (ICU)afternon-cardiac surgery.193 Anticoagu-
lation must be based on the individual clinical situation.
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Perioperative bradyarrhythmias usually respond well to short-
term pharmacological therapy; temporary cardiac pacing is
rarely required. Prophylactic pacing before non-cardiac surgery
is not commonly indicated. Pre-operative establishment of tem-
porary or permanent cardiac pacing may be appropriate for
patients with complete heart block or symptomatic asystolic epi-
sodes. The indications for temporary pacemakers during the peri-
operative period are generally the same as those for permanent
pacemakers. Asymptomatic bifascicular block, with or without
first-degree atrioventricular block, is not an indication for tempor-
ary pacing; however, the availability of an external pacemaker for
transcutaneous pacing is appropriate.
5.4.4 Perioperative management of patients with
pacemaker/implantable cardioverter defibrillator
Patients with a permanent pacemaker can safely undergo surgery if
appopriate precautions are taken.194 The use of unipolar electro-
cautery represents a significant risk, as the electrical stimulus from
electrocautery may inhibit ’demand’ pacemakers, or may reprogram
the pacemaker. These problems can be avoided or minimized by
using bipolar electrocautery, correct positioning the ground plate
for the electrical circuit. Keeping the electrocautery device away
from the pacemaker, giving only brief bursts, and using the lowest
possible amplitude may also decrease the interference. The pace-
maker should be set in an asynchronous or non-sensing mode in
patients who are pacemaker-dependent. This is most easily done in
the operating room by placing a magnet on the skin over the pace-
maker. Patients whose underlying rhythm is unreliable should have
pacemaker interrogation after surgery, to ensure appropriate pro-
gramming and sensing-pacing thresholds.
Interferencewith the function of implantable cardioverter defibril-
lators (ICD) can also occur during non-cardiac surgery, as a result of
the electrical current generated by electrocautery. The ICD should
be turned off during surgery and switched on in the recovery phase
before discharge to the ward. The defibrillator function of an ICD
can be temporarily deactivated by placing a magnet on the skin
over the ICD. While the device is deactivated, an external defibrilla-
tor should be immediately available.
Recommendations for ventricular arrhythmias
Recommendations Classa Levelb
Continuation of oral anti-
arrhythmic drugs before surgery is 
recommended.
I C
Anti-arrhythmic drugs are 
recommended for patients with 
sustained VT, depending on the 
patient’s characteristics.
I C
Anti-arrhythmic drugs are not 
recommended for patients with 
VPBs.
III C
VT ¼ ventricular tachycardia; VPB ¼ ventricular premature beats.
aClass of recommendation.
bLevel of evidence.
Recommendations on supraventricular arrhythmias
Recommendations Classa Levelb
Continuation of oral anti-
arrhythmic drugs before surgery is 
recommended.
I C
Electrical cardioversion when 
haemodynamic instability occurs is 
recommended.
I C
Vagal manoeuvres and anti-
arrhythmic therapy for termination 
of SVT in haemodynamically stable 
patients is recommended.
I C
SVT ¼ supraventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
Recommendations on bradyarrhythmias and
pacemakers
Recommendations Classa Levelb
The indications for temporary 
pacemakers during the peri-operative 
period are generally the same as those 
for permanent pacemakers.
I C
It is recommended that the hospital 
nominate a person who is responsible for 
programming of the implanted arrhythmia
devices before and after surgery.
I C
Patients with ICDs, whose devices have
been pre-operatively deactivated, should 
be on continuous cardiac monitor 
throughout the period of deactivation. 
External defibrillation equipment should 
be readily available.
I C
Patients who have asymptomatic 
bifascicular or trifascicular block are not 
recommended for routine management






Impaired renal function is associated with a significantly increased risk
of CVD and is an independent risk factor for adverse post-operative
cardiovascularoutcomes, includingmyocardial infarction, stroke, and
progression of heart failure. The development of acute kidney injury
(AKI) after major surgery reduces long-term survival in patients with
normal baseline renal function.195 Risk factors for the development
of post-operative AKI following non-cardiac surgery have been iden-
tified and include age .56 years, male sex, active cardiac failure,
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presence of ascites, hypertension, emergency surgery, intraperito-
neal surgery, pre-operative creatinine elevation, and diabetes mellitus.
Patients with ≥6 of these factors have a 10% incidence of AKI, and a
hazard ratio of 46 as compared with those with ,3 risk factors.196
Further, the relationship between chronic kidney disease (CKD)
and cardiovascular morbidity/mortality is independent of hyperten-
sion and diabetes.
Chronic kidney disease is defined as impaired kidney function or
raised proteinuria, confirmed on two or more occasions at least
three months apart. Here, the estimated glomerular filtration rate
(eGFR) should be calculated using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) formula, which uses sex, age,
ethnic origin, and serum creatinine concentration. Additionally, pro-
teinuria should be assessed using the urinary albumin–creatinine
ratio. Chronic kidney disease is thus classified into six stages of
eGFR and three stages of proteinuria.197 A comparison of the most
recent definitions of AKI is shown in Table 7.
Renal function can be calculated routinely using the Cockcroft-
Gault formula, or an eGFR calculated from serum creatinine using
the Modification of Diet in Renal Disease (MDRD) study or the
CKD-EPI equations. The use of newer biomarkers in the diagnosis of
AKI is still under investigation. Normal GFR values are 100–130 mL/
min/1.73 m2 in young men, and 90–120 mL/min/1.73 m2 in young
women, and vary depending on age, sex, and body size. A cut-off
GFR value of ,60 mL/min/1.73 m2 correlates significantly with
major cardiovascular adverse events. Identification of patients at risk
of perioperative worsening of renal function is important, in order
to initiate supportive measures such as maintenance of adequate intra-
vascular volume for renal perfusion and use of vasopressors.198
Susceptibility to developing AKI after exposure to a specific
insult has been identified according to a number of observational
studies.199 The most frequent causes for AKI in hospitalized
cardiac patients relate to the combination of a low cardiac
output/high venous pressure, and/or the administration of iodi-
nated contrast media during diagnostic and interventional vascu-
lar procedures. Contrast-induced AKI (CI-AKI) is defined as a
rise of serum creatinine of 44 mmol/L (0.5 mg/dL) or a 25% rela-
tive rise from baseline at 48 hours (or 5–10% at 12 hours) fol-
lowing contrast administration. It occurs in up to 15% of
patients with chronic renal dysfunction who are undergoing
radiographic procedures.200 Although most cases of CI-AKI are
self-limiting, with renal function returning to normal within 7
days of the procedure, these patients occasionally (in 0.5–12%
of cases) develop overt renal failure, associated with increased
morbidity and mortality. In some, severe renal impairment
necessitates renal-replacement therapy and can lead to perman-
ent renal injury. The pathogenesis of CI-AKI is multifactorial, and
is thought to include a decrease in glomerular filtration and renal
hypoperfusion, together with renal medullary ischaemia, direct
tubular toxicity via reactive oxygen species, and direct cellular
toxicity from the contrast agent.
A numberof risk factor scoring systems exist for predicting CI-AKI.
These include the urgency of the procedure, baseline renal function,
diabetes, and contrast volume. A range of strategies has been pro-
posed to prevent CI-AKI, including minimizing the volume of contrast
medium administered, use of less-nephrotoxic contrast agents, pro-
vision of prophylactic renal-replacement therapy, patient hydration,
and use of pharmacological agents to counteract the nephrotoxicity
of contrast agents.198
The relationship between the volume of contrast agent ad-
ministered and the development of CI-AKI is well known, and
exceeding the maximum contrast dose (contrast volume/eGFR) is
Table 7 Summary of definitions of acute kidney injury
AKI ¼ acute kidney injury; AKIN ¼ Acute Kidney Injury Network; ESRD ¼ end-stage renal disease; GFR ¼ glomerular filtration rate; KDIGO ¼ Kidney Disease: Improving Global
Outcomes; RIFLE ¼ Risk, Injury, Failure, Loss, End-stage renal disease; RRT ¼ renal replacement therapy.
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strongly associated with the development of CI-AKI. The impact of
the osmolality of contrast agent on nephrotoxicity has been
evaluated in a number of randomized controlled trials, with dissimilar
results; however, based on a number of meta-analyses, the use of low
osmolar contrast media (LOCM) or iso-osmolar contrast media
(IOCM) is recommended in patients with mild, moderate, or
severe CKD, who are undergoing contrast-enhanced radiography.
Numerous studies have addressed the use of renal-replacement
therapies to prevent CI-AKI.201 Although renal-replacement
therapy has a favourable effect, in terms of reducing CI-AKI (relative
risk 0.19; P, 0.001) in patients with stage 4 or 5 CKD, haemodialysis
has been found to be non-beneficial (and potentially harmful) for the
prevention of CI-AKI in those with baseline CKD stage ≤3.
Recommendations on renal function
Recommendations Classa Levelb Ref. c
Patients undergoing contrast-enhanced radiographic
procedures
Patients should be assessed 
for risk of CI-AKI. IIa C
Prevention of contrast-induced nephropathy in
patients with moderate or moderate-to-severe CKD 
Hydration with normal 
saline is recommended 
before administration of 
contrast medium.
I A 198
Use of LOCM or IOMC is 
recommended. I A 198
It is recommended that the 
volume of contrast media
be minimized.
I B 198
Hydration with sodium 
bicarbonate should be 
considered before 




statin therapy should be 
considered.
IIa B 203
Patients with severe CKD
In patients with stage 4 or 
5 CKD, prophylactic 
haemofiltration may be 
considered before complex 
intervention or high-risk 
surgery.
IIb B 201





CI-AKI ¼ contrast-induced acute kidney injury; CKD ¼ chronic kidney disease;
GFR ¼ glomerular filtration rate; IOMC ¼ iso-osmolar contrast medium;




Pre-procedural hydration with intravenous isotonic fluids is the
most effective method of reducing the risk of CI-AKI.198 Normal
saline or isotonic sodium bicarbonate (1.26%) may be used and per-
ipherally administered, with the advantage that it requires only one
hour of pre-treatment and may therefore present the preferred
option in patients scheduled for urgent or outpatient proce-
dures.202 N-acetyl cysteine may be considered for prophylaxis of
CI-AKI, given its low cost and toxicity profile; however, the evi-
dence for its benefit remains inconclusive. A number of small
studies undertaking alkalinization of urine using a range of agents
(bicarbonate, sodium/potassium citrate, acetazolamide) have
shown a reduction in the incidence of contrast-induced nephropa-
thy; recent information suggesting the use of high-dose statins in
preventing CI-AKI is promising.203 Although there are theoretical
benefits from the use of loop diuretics in early or established AKI,
these have not been supported by data in studies, and diuretics
are therefore not recommended for the prevention or treatment
of AKI.198
5.6 Cerebrovascular disease
The majority of the literature on perioperative stroke focuses on
cardiac surgery, with an event rate ranging from 2–10%, according
to the type of operation.204 With respect to non-cardiac surgery,
perioperative stroke has been reported in 0.08–0.7% of patients
undergoing general surgery, in 0.2–0.9% of patients requiring
orthopaedic surgery, in 0.6–0.9% of lung operations, and in 0.8–
3.0% of surgeries involving the peripheral vasculature.204,205 The
associated mortality ranges from 18–26%.204,205 A more recent
analysis on 523 059 patients undergoing non-cardiac surgery
reported a lower incidence of perioperative stroke (0.1%).206
The occurrence of this adverse event was associated with a
700% increase in perioperative mortality, corresponding to an ab-
solute risk increase exceeding 20%. Multivariate analysis identified
age, history of myocardial infarction within 6 months prior to
surgery, acute renal failure, history of stroke, history of TIA, dialysis,
hypertension, chronic obstructive pulmonary disease (COPD),
and current tobacco use as independent predictors of periopera-
tive stroke, while high body mass index was found to be
protective.206
Perioperative strokes are mainly ischaemic and cardioembolic
and AF is often the underlying leading condition. Triggers
include the withdrawal of anticoagulation and the hypercoagul-
able state related to surgery. Additional aetiologies include ather-
oembolism, originating from the aorta or the supra-aortic vessels,
and local atherothrombosis in the presence of intracranial small-
vessel disease. Hypoperfusion—related to perioperative arterial
hypotension and/or severe stenosis of the cervicocranial
vessels—is an unusual cause of perioperative stroke.207 Rarely,
perioperative stroke may be due to air, fat, or paradoxical
embolisms.
In an attempt to attenuate the risk of perioperative stroke, anti-
platelet/anticoagulant treatments should be continued whenever
possible throughout the perioperative period. Alternatively, the
period of drug withdrawal should be kept as short as possible while
weighting thrombo-embolic and haemorrhagic risks (see sections
4.2 and 4.3). Adequate selection of the anaesthetic technique
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(regional vs. neuraxial vs. general anaesthesia), prevention and treat-
ment of AF, euglycaemic control (avoiding both hyperglycaemia and
hypoglycaemia), as well as meticulous perioperative blood pressure
control, may all contribute to reducing the risk of perioperative
stroke.
Patients undergoing non-cardiac surgery should be questioned
about previous neurological symptoms, and those with symptoms
suggestive of TIA or stroke in the preceding 6 months should
undergo pre-operative neurological consultation as well as neuro-
vascular and brain imaging, where appropriate. In the absence of
dedicated studies addressing this issue, the criteria for carotid
revascularization described in the 2011 ESC Guidelines on the
diagnosis and treatment of peripheral artery disease should also
guide the management of patients with carotid disease, who are
undergoing non-cardiac surgery.19 In patients with symptomatic
carotid disease (i.e. with a stroke or TIA affecting the correspond-
ing vascular territory in the preceding 6 months), carotid revascu-
larization should performed first and non-cardiac surgery
postponed.
Owing to the increasing average age of the population, an in-
creasing number of patients referred for non-cardiac surgery
may have associated asymptomatic carotid artery disease.
According to a meta-analysis of studies covering a total of 4573
patients with PAD, the rates of asymptomatic carotid stenosis
.50% and .70% were 25% and 14%, respectively.208 Carotid
imaging, while not indicated routinely in patients undergoing non-
cardiac surgery, may be considered before vascular surgery, due
to the high prevalence of carotid artery disease in this patient
group.
The question as to whether patients with severe asymptomatic
carotid occlusive disease, who are undergoing elective major non-
cardiac surgery, require pre-operative carotid revascularization
remains a matter of debate. Importantly, the purpose of carotid
revascularization in this setting is more the long-term prevention
of stroke than perioperative stroke reduction; therefore, if
carotid revascularization is indicated, this may be performed
before or after the planned non-cardiac surgery. Independently of
the revascularization strategy, patients with carotid artery stenosis
benefit from aggressive cardiovascular risk-factor modification to
prevent perioperative myocardial ischaemia. Accordingly, patients
with carotid artery disease suffer a high incidence of CAD. In a pro-
spective investigation in 390 patients undergoing elective carotid
artery revascularization, systematic coronary angiography showed
the presence of one-, two-, and three-vessel disease, and left main
coronary stenoses in 17%, 15%, 22%, and 7% of patients, respective-
ly.209 Consequently, statins should be continued; whenever pos-
sible aspirin and beta-blockers should not be withdrawn, and
blood pressure should be carefully controlled (see sections 4.1
and 5.2).
Apart from TIA or stroke, transient or even permanent changes in
mental status may occur following non-cardiac surgery, including
spatio-temporal disorientation, memory loss, hallucinations,
anxiety or depression. These findings may especially be encountered
in patients with known cognitive impairment. The underlying
mechanisms, often elusive, may include surgery-induced systemic in-
flammation and cerebral hypoperfusion.
Recommendations on patients with suspected or
established carotid artery disease
Recommendations Classa Levelb
Pre-operative carotid artery and 
cerebral imaging are recommended in 
patients with a history of TIA or stroke 
in the preceding 6 months.
I C
Pre-operative, routine carotid artery 
imaging may be considered in patients 
undergoing vascular surgery.
IIb C
Whenever possible, continuation of 
anti-platelet and statin therapies should 
be considered throughout the peri-
operative phase in patients with carotid 
artery disease.
IIa C
For patients with carotid artery disease 
undergoing non-cardiac surgery, the 
same indications for carotid 
revascularization should apply as for 
the general population.
IIa C
Pre-operative routine carotid artery 
imaging is not recommended in 
patients undergoing non-vascular 
surgery.
III C
TIA ¼ transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
5.7 Peripheral artery disease
Patients with PAD (defined as an ankle–brachial ratio of ,0.9, or
previously revascularized with surgery or percutaneous transluminal
angioplasty) usually have advanced atherosclerotic disease affecting
most vascular beds in varying degrees and have a worse prognosis
than patients without PAD.210,211 Even in patients without known
CAD, peripheral artery surgery is associated with an increased inci-
dence of perioperative acute myocardial infarction.212 Peripheral
artery disease is thus an established risk factor for non-cardiac
surgery and it is reasonable to assess the presence of IHD from the
patient’s history and routine clinical examinations and tests;
however, it is not recommended to routinely perform exercise or
imaging test to detect cardiac ischaemia in PAD patients without clin-
ical symptoms, unless thepatienthasmore than twoof the clinical risk
factors detailed in Table 4. In a randomized trial, prophylactic coron-
ary revascularization before major vascular surgery in stable PAD
patients did not reduce the incidence of major clinical endpoints.152
However, patients with severely reduced LV function or left main
disease were excluded.
All patients with PAD should be treated with statins and platelet
inhibitors according to guidelines.211 Blood pressure control and life-
style measures should be attended to, as recommended in the ESC
Guidelines on cardiovascular prevention.210 It is not recommended
that beta-blocker therapy be routinely initiated pre-operatively
unless there are other indications, such as heart failure or ischaemic
coronary disease (see section 4.1).
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Patients with PAD should be clinically 
assessed for ischaemic heart disease and, if 
more than two clinical risk factors (Table 4) 
are present, they should be considered for 
pre-operative stress or imaging testing.
IIa C




The co-existence of pulmonary disease in patients undergoing non-
cardiac surgery may increase the operative risk. Such diseases
include acute respiratory infections, COPD, asthma, cystic fibrosis,
interstitial lung disease, and other conditions causing impairment of
respiratory function. Pre-existing pulmonary disease has a significant
impact on perioperative risk, but the most common effect is to in-
crease the risk of post-operative pulmonary complications. These
complications are in part a consequence of the development of atel-
ectasis during general anaesthesia; however, factors that result in
post-operative hypoventilation, reduced tidal volumes, and impaired
lung expansion may cause persistent lung collapse and increase the
risk of respiratory infection. These complications occur particularly
after abdominal or thoracic surgery, and the risk seems to be
increased in smokers. Certain respiratory conditions are associated
with cardiovascular pathology and may require special cardiac risk as-
sessment and management, in addition to dealing with pulmonary
disease per se. Three such conditions are COPD, obesity hypoventi-
lation syndrome (OHS), and pulmonary artery hypertension (PAH).
COPD is characterized by airflow obstruction that is usually pro-
gressive, not fully reversible, and does not change markedly over
several months. The disease is predominantly caused by smoking
and is well-recognized as a major cause of morbidity and mortality.213
The prevalence of COPD in Europe is 4–10% of adults, therefore up
to one patient in ten undergoing non-cardiac surgery may have
COPD. Cor pulmonale with associated right-heart failure may be a
direct complication of severe COPD; however, COPD is also asso-
ciated with an increased risk of CAD. COPD is a risk factor for
IHD and sudden death by unknown mechanisms, although there
are several shared risk factors for both types of disease (smoking, dia-
betes, hypertension, systemic inflammation, increased plasma fi-
brinogen). Epidemiological evidence suggests that reduced forced
expiratory volume in 1 second (FEV1) is a marker for cardiovascular
mortality, independent of age, gender, and smoking history, with a
30% increase in cardiovascular mortality and 20% increase in non-
fatal coronary events for every 10% decrease in FEV1.
213 Although
patients with COPD have an increased risk of CVD, there is no evi-
dence that COPD is related to a higher risk of perioperative
cardiac complications. Post-operative pulmonary complications
result in significant mortality and morbidity, however. Pre-operative
evaluation, using specific post-operative pulmonary complication
tools, can be used to stratify patients at risk and allow optimal pre-
operative and perioperative management.214
In patients with COPD who are having non-cardiac surgery, the
pre-operative treatment goals are to optimize pulmonary function
and minimize post-operative respiratory complications; this includes
using the pre-operative period for education, including possible ces-
sation of smoking (.2 months before surgery), instruction in chest
physiotherapy and lung expansion manoeuvres, muscular endurance
training, and re-nutrition if required. Beta-adrenergic agonists and
anticholinergic agents should be continued until the day of surgery
in all symptomatic COPD patients with bronchial hyper-reactivity.
In some cases, short-term systemic/inhaled steroids may be consid-
ered. Any associated ventricular failure should be managed accord-
ingly. Where there is active pulmonary infection, appropriate
antibiotics should be administered for at least 10 days and, if possible,
surgery should be delayed.215
OHS is defined as the triad of obesity, daytime hypoventilation, and
sleep-disordered breathing. Although distinct from simple obesity and
sleep apnoea, it is estimated that 90% patients with OHS also have ob-
structive sleep apnoea. The prevalence of OHS is 0.15–3% of adults,
and 7–22% in patients undergoing bariatric surgery.216 Obesity and ob-
structive sleep apnoea are associated with a number of comorbidities
including CAD, heart failure, stroke, and metabolic syndrome. OHS is
associated with even higher morbidity, including heart failure (and
obesity-related cardiomyopathy), angina pectoris, pulmonary hyperten-
sion (30–88%) and cor pulmonale, and increased perioperative mortal-
ity.216 Pre-operatively, the presence of a high body mass index and
apnoea–hypopnea index should alert the physician to screen for
OHS, including the use of screening questionnaires, peripheral
oxygen saturations, and serum bicarbonate levels. Patients at high risk
of OHS who are undergoing major surgery should be referred for add-
itional specialist investigation for sleep disordered breathing and pul-
monary hypertension, with pre-operative initiation of appropriate
positive airway pressure therapy, and planning of perioperative techni-
ques (anaesthetic and surgical) andpost-operative positive airway pres-
sure management within an appropriate monitored environment.216
Pulmonary hypertension is a haemodynamic and pathophysio-
logical condition, defined as an increase in mean pulmonary arterial
pressure.25 mm Hg at rest, as assessed by right heart catheteriza-
tion, and can be found in multiple clinical conditions.217 Pulmonary
artery hypertension (PAH) is a clinical condition, characterized by
the presence of pre-capillary pulmonary hypertension in the
absence of other causes, such as pulmonary hypertension due to
lung diseases, chronic thrombo-embolic pulmonary hypertension,
or other rare diseases. Pulmonary artery hypertension includes dif-
ferent forms that share a similar clinical picture and virtually identical
pathological changes of the lung microcirculation.217 From surveys
and population studies, the prevalence of PAH is reported to be
between 15–150 cases per million adults, with approximately 50%
of cases being idiopathic. The prevalence is thus low and consequent-
ly the condition is uncommon in surgical practice. Pulmonary artery
hypertension is associated with increased post-operative complica-
tions, including right ventricular failure, myocardial ischaemia, and
post-operative hypoxia and, in patients undergoing cardiopulmonary
bypass surgery, a mean pre-operative pulmonary artery pressure
.30 mm Hg is an independent predictor of mortality. In patients
with pulmonary hypertension undergoing non-cardiac surgery,
outcome predictors include New York Heart Association functional
Class .III, intermediate to high-risk surgery, right ventricular
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dysfunction, and long duration of anaesthesia. This condition has an
associated perioperative cardiopulmonary complication rate of
38%, and mortality of 7%.218,219 The initial approach after diagnosing
PAH is the adoption of general measures and supportive therapy, and
referral to an expert centre for initiation of advanced pulmonary
hypertensive therapies. Owing to the potential for anaesthesia and
surgery to be complicated by acute right heart failure and pulmonary
hypertensive crisis, surgical interventions inpatientswith PAHshould
be avoided unless absolutely necessary. Ideally, patients with PAH
Recommendations on PAH and pulmonary diseases
Recommendations Classa Levelb Ref. c
It is recommended that patients with
severe PAH, who are undergoing
elective surgery, be managed in a
centre with appropriate expertise. 
I C 217
It is recommended that interventions
for high-risk patients with PAH be
planned by the multidisciplinary




It is recommended that patients with 
PAH have an optimized treatment
regimen before any non-emergency
surgical intervention.   
I C 217
It is recommended that patients
receiving PAH-specific treatment




It is recommended that monitoring
of patients with PAH continue for at
least 24 hours in the post-operative
period.  
I C
In the case of progression of right
heart failure in the post-operative
period of patients with PAH, it is
recommended that the diuretic dose
be optimized and, if necessary,
intravenous vasoactive drugs be
initiated under the guidance of a
physician experienced in the




In patients with COPD, smoking
cessation (>2 months before surgery)
is recommended before undertaking
surgery.   
I C
In the case of severe right heart
failure that is not responsive to
supportive therapy, the temporary
administration of pulmonary
vasodilators (inhaled and/or
intravenous) is recommended, under
the guidance of a physician
experienced in PAH.  
I C 217
In patients at high risk of OHS
additional specialist investigation
before major elective surgery should
be considered. 
IIa C 216




who are undergoing surgery should have an optimized treatment
regimen before any surgical intervention, and be managed in a
centre with appropriate expertise. Interventions for high-risk
patients should be planned by the multidisciplinary pulmonary hyper-
tension team. Patients receiving PAH-specific therapy must not have
drugs withheld for the pre-operative fasting state, and may require
temporary conversion to intravenous and/or nebulized treatment
until they are able to reliably absorb via the enteral route. As the
highest mortality is in the post-operative period, it is recommended
that facilities for appropriate monitoring should be available, and
monitoring continued for at least 24 hours. In case of progression
of right heart failure in the post-operative period, it is recommended
that the diuretic dose should be optimized and, if necessary, inotropic
support with dobutamine be initiated. Starting new, specific PAH
drug therapy in the perioperative period has not been established.
In the case of severe right heart failure that is not responsive to sup-
portive therapy, the temporary administration of pulmonary vasodi-
lators (inhaled and/or intravenous) may be considered, under the
guidance of a physician experienced in PAH.
5.9 Congenital heart disease
Children, adolescents and adults with congenital heart disease are
generally regarded as being at increased risk when undergoing non-
cardiac surgery but this risk will vary enormously, according to the
degree of associated heart failure, pulmonary hypertension, arrhyth-
mias, and shunting of blood—with or without associated oxygen de-
saturation and by the complexity of the underlying condition.222 A
thorough understanding of the underlying congenital heart disease,
including anatomy, physiology, and identification of risk factors, is
vital before surgery. When the defect is simple, the circulation physio-
logicallynormaland thepatientwell compensated, the riskmaybequite
low; however, complicated patients with congenital heart disease
should only undergo non-cardiac surgery after thorough evaluation
byamultidisciplinary team in a specialized centre. Prophylaxis forendo-
carditis shouldbe initiated according to the ESCGuidelines oncongeni-
tal heart disease and infective endocarditis.190,222
Recommendation on patients with congenital heart
disease
Recommendation Classa Levelb
It is recommended that, patients with 
complex congenital heart disease be 
referred for additional specialist 
investigation before undergoing elective 






Continuous ECG monitoring is recommended for all patients under-
going anaesthesia. The patient should be connected to the ECG
ESC/ESA Guidelines2416





monitor before induction of anaesthesia or institution of a regional
block. The duration of ST-segment changes correlates positively
with the incidence of perioperative myocardial infarction; 223 there-
fore, when ST-segment changes occur, the clinician should assume
that myocardial ischaemia is present if the patient has a history of
pre-existing cardiac disease or is undergoing surgery.
It is not clear, however, whether ECG monitoring is sufficiently
sensitive to identify patients with myocardial ischaemia. In addition,
ECG monitoring is of limited value in patients who have intraventri-
cular conductiondefects and ventricular paced rhythms. In one study,
Holter recordings were used as the reference standard for detection
of intra-operative ischaemia and the ST-trending monitors were
found to have overall sensitivity of 74% and specificity of 73%.224
The choice and configuration of the leads used for monitoring may
influence the ability to detect significant ST-segment changes. Al-
though V5 has for many years been regarded as the best choice for
the detection of intra-operative ischaemia, one study found that V4
was more sensitive and appropriate than V5 for detecting prolonged
post-operative ischaemia and infarction.225
As many ischaemic events are dynamic and may not always be
detected by the same lead, reliance on a single lead for monitoring
results in a greater risk of failing to detect an ischaemic event. With
the use of selected lead combinations, more ischaemic events can be
precisely diagnosed in the intra-operative setting. In one study, although
the best sensitivity was obtained with V5 (75%), followed by V4 (61%),
combining leads V4 and V5 increased the sensitivity to 90%. When the
leads II, V4 and V5 were used simultaneously, the sensitivity was greater
than 95%.225,226 In another study, in which two or more pre-cordial
leads were used, the sensitivity of ECG monitoring was greater than
95% for detection of perioperative ischaemia and infarction.225 It was
also shown that ECG monitoring with fewer leads (as few as three)
has lower sensitivity than monitoring with 12 leads and there is a stat-
istically significant association, independent of perioperative troponin
values, between perioperative ischaemia on a 12-lead ECG and long-
term mortality.227,228 Thus, 12-lead ECG monitoring is recommended
especially in high-risk patients, although correct positioning of 12 leads
is not feasible in high abdominal and thoracic surgery.
Recommendations on ECG monitoring
Recommendations Classa Levelb Ref. c
Peri-operative ECG monitoring is
recommended for all patients
undergoing surgery.  
I C
Selected lead combinations should be 
considered for better detection




When feasible, twelve-lead ECG
monitoring should be considered










Transoesophageal echocardiography (TOE) has frequently been
used as a monitoring tool during cardiac surgery. TOE has
several advantages. It is rapidly available, relatively non-invasive,
and provides more versatile and comprehensive information;
however, although TOE is in general a safe procedure, serious
adverse events can occur. The complication rates relate to the ex-
perience of the operator and the presence of oesophageal or
gastric diseases. Specific training of users is essential to avoid in-
accurate interpretation.
Myocardial ischaemia can be identified by abnormalities in re-
gional wall motion and thickening. The agreement between
intra-operative TOE and ECG is rather weak.229 Both ST-segment
changes and regional wall motion abnormalities can be present in
the absence of acute ischaemia. Wall motion abnormalities may
be difficult to interpret in the presence of left bundle branch
block, ventricular pacing, or right ventricular overload. The reso-
lution of ischaemia is not necessarily detectable if ischaemia is fol-
lowed by myocardial stunning. Episodes of new or worsened wall
motion abnormalities have been shown to be relatively infrequent
(20%) in high-risk patients undergoing non-cardiac surgery.229
They were more common in patients submitted to aortic vascular
surgery. Episodes were poorly correlated with post-operative
cardiac complications.229
For the purpose of identifying patients at high risk of perioperative
ischaemic outcomes, routine monitoring for myocardial ischaemiawith
TOEor 12-lead ECG during non-cardiac surgery is of little more clinical
value than pre-operative clinical data and intra-operative monitoring
using a 12-lead ECG.230
TOE is recommended if acute and severe haemodynamic
instability or life-threatening abnormalities develop during or after
surgery.231 It is a useful technique in the context of hypotension
during non-cardiac surgery. In a prospective study including 42
adults, TOE was performed before any other haemodynamic moni-
toring when severe hypotension developed. It was useful for deter-
mining the cause of severe hypotension, hypovolaemia, low
ejection fraction, severe embolism, myocardial ischaemia, cardiac
tamponade, or dynamic LV outflow tract obstruction.232 The value
of TOE for systematic haemodynamic monitoring in patients at
risk is more controversial. There is no evidence that haemodynamic
monitoring by TOE accurately stratifies risk or predicts outcome.
TOE can be useful in the operating room in patients with severe
valvular lesions. The loading conditions during general anaesthesia
differ from those present in the pre-operative evaluation. Second-
ary mitral regurgitation is usually reduced during general anaesthe-
sia; on the other hand, primary mitral regurgitation can increase. In
the setting of severe mitral regurgitation, the LVEF overestimates
LV function and other parameters may be more accurate, such as
myocardial deformation obtained by two-dimensional speckle
tracking. More validation is needed before this method can be
used routinely in this setting. In patients with severe aortic stenosis,
appropriate pre-load is important during surgery. Monitoring of LV
end-diastolic volume with TOE may be more accurate than by pul-
monary capillary pressure. An appropriate heart rate is crucial in
patients with mitral stenosis and aortic regurgitation: a sufficient
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diastolic period in the former and an appropriate—not long—dur-
ation of diastole in the latter. When inappropriate control of heart
rate occurs, the consequences should be assessed: changes in trans-
mitral mean gradient and pulmonary artery pressures in mitral sten-
osis, and changes in LV volumes and indices of LV function in aortic
regurgitation.
Recommendations on intra-operative and/or
perioperative TOE for detection of myocardial
ischaemia
Recommendations Classa Levelb Ref. c
The use of TOE should be considered
in patients who develop ST-segment
changes on intra-operative or
peri-operative ECG monitoring. 
IIa C 230
The use of TOE may be considered
in patients at high risk of developing
myocardial ischaemia, who
undergo high-risk non-cardiac surgery. 
IIb C 230




Recommendations on intra-operative and/or
perioperative TOE in patients with or at risk of
haemodynamic instability
Recommendations Classa Levelb Ref. c
TOE is recommended when acute 
sustained severe haemodynamic 
disturbances develop during 
surgery or in the peri-operative 
period.
I C 235
TOE monitoring may be 
considered in patients at increased 
risk of significant haemodynamic 
disturbances during and after high-
risk non-cardiac surgery.
IIb C
TOE monitoring may be 
considered in patients who 
present severe valvular lesions 
during high-risk non-cardiac 
surgery procedures accompanied 
by significant haemodynamic 
stresses.
IIb C




Transoesophageal Doppler (TOD) (without echocardiography)
can be also used to monitor cardiac output. A government-
sponsored systematic review performed in the USA concluded
that a strong level of evidence existed to support the usefulness of
TOD in reducing the rate of major complications and the length of
hospital stay after major surgery.233 A similar conclusion was
drawn in a separate review commissioned by the UK’s National
Health Service (NHS) Centre for Evidence-based Purchasing, per-
formed in three NHS hospitals, with 626 patients being assessed
before- and 621 patients after implementation of an intra-operative
TOD-guided fluid optimization strategy. The findings of the NHS
review showed a 67% decrease in intra-operative mortality, a 4-day
reduction in mean duration of post-operative hospital stay, a 23% re-
duction in the need for central venous catheter insertion, a 33% de-
crease in complication rates, and a 25% reduction in re-operation
rate.234
6.3 Right heart catheterization
Despite more than 30 years’ experience with the pulmonary artery
catheter (PAC) and right heart catheterization, little evidence
exists in the medical literature to demonstrate a survival benefit asso-
ciated with PAC in perioperative patients. A case-control analysis,
carried out in a subset of patients from a large observational study
who underwent PAC placement, and who were matched with a
similar number of patients who did not undergo right heart catheter-
ization, demonstrated a higher incidence of post-operative heart
failure and non-cardiac events than the control group.236
Similarly, a Cochrane review of 12 randomized, controlled clinical
trials studying the impact of PAC in a large spectrum of patients—in-
cluding patients whowere undergoing surgeryor whowereadmitted
to the ICU with advanced heart failure, acute respiratory distress syn-
drome, or sepsis—failed to demonstrate a difference in mortality and
length of hospital stay, suggesting that PAC does not provide informa-
tion that is not otherwise available to select a treatment plan.237
Routine PAC and right heart monitoring is therefore not re-
commended in patients during non-cardiac surgery. The use of
other non-invasive perioperative cardiac output monitoring techni-
ques (including TOE with Doppler monitoring) to optimize cardiac
output and fluid therapy in high-risk patients undergoing non-cardiac
surgery, seems to be associated with reduction in length of stay and
complications,238 yet convincing data on hard end-points are still
lacking.
6.4 Disturbed glucose metabolism
Diabetesmellitus is the most common metabolic disorder in Europe,
with a prevalence of 6.4% in 2010, which is predicted to increase to
7.7% by 2030.239 Type 2 diabetes accounts for .90% of cases, and
is expected to increase, probably due to the obesity epidemic in
children and young adults. The condition promotes atheroscler-
osis, endothelial dysfunction, activation of platelets, and synthesis
of pro-inflammatory cytokines. According to the World Health
Organization, approximately 50% of patients with type 2 diabetes
die of CVD. It is well established that surgery in patients with dia-
betes is associated with longer hospital stay, greater use of health-
care resources, and higher perioperative mortality. Elevated levels
of glycosylated haemoglobin (HbA1c)—a marker of poor glycaemic
control—are associated with worse outcomes in surgical and crit-
ical care patients.240 Further, surgical stress increases the pro-
thrombotic state, which may present a particular issue in patients
with diabetes; thus diabetes is an important risk factor for peri-
operative cardiac complications and death. Critical illness is also
characterized by dysglycaemia, which may develop in the absence
of previously diagnosed diabetes, and has repeatedly been
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identified as an important risk factor for morbidity and mortality.240
More recently, the emphasis has shifted from diabetes to hypergly-
caemia, where new-onset hyperglycaemia (compared with hyper-
glycaemia in known diabetics) may hold a much higher risk of
adverse outcome.240,241 Studies in the field of critical care have
demonstrated the detrimental effect of hyperglycaemia, due to
an adverse effect on renal and hepatic function, endothelial func-
tion, and immune response, particularly in patients without under-
lying diabetes. Oxidative stress (a major cause of macrovascular
disease) is triggered by swings in blood glucose, more than by sus-
tained and persistent hyperglycaemia. Minimization of the degree of
glucose variability may be cardioprotective, and mortality may cor-
relate more closely with blood glucose variability than mean blood
glucose per se.240,241
A significant number of surgical patients will have previously un-
diagnosed pre-diabetes, and are at increased risk of unrecognised
perioperative hyperglycaemia and the attendant adverse out-
comes. Although there is no evidence that screening low- or
moderate-risk adults for diabetes improves outcomes, it may
reduce complications in high-risk adults. Screening patients using
a validated risk calculator (e.g. FINDRISC) can identify high or
very high-risk adults; this can be followed up by screening every
3–5 years with HbA1C.
242,243 In patients with diabetes, pre-
operative or pre-procedural assessment should be undertaken
to identify and optimize comorbidities, and determine the peri-
procedural diabetes management strategy. For non-cardiac
surgery patients without known diabetes, evidence for strict
blood glucose control is derived largely from studies in critically
ill patients, and is disputed.240,241 Early randomized controlled
trials of intensive insulin therapy maintaining strict glycaemic
control showed morbidity benefits in medical patients in
ICUs, and reduced mortality and morbidity in surgical patients
in ICUs. Subsequent studies, however, found a reduction in
mortality in those whose blood glucose control was less strict
[7.8–10 mmol/L (140–180 mg/dL)] than in those in whom it was
tightly controlled [4.5–6 mmol/L (81–108 mg/dL)], as well as
fewer incidents of severe hypoglycaemia. Subsequent meta-
analyses have demonstrated no reduction in 90-day mortality with
intensive blood glucose control but a five- to six-fold incidence of
hypoglycaemia.240,241 Several suggestions have been put forward
to explain the differences in outcome between these studies,
includingenteral vs. parenteral feeding, the target for insulin initiation,
compliance with therapy, accuracy of glucose measurements,
mechanism or site of insulin infusion, type of protocol used, and
the nurse’s level of experience. In addition, there is disagreement
on the timing of the initiation of insulin therapy: tight intra-operative
glucose control may provide benefit but appears to be difficult and,
thus far, studies have mainly been undertaken in patients undergoing
cardiac surgery.
The correlation of poor surgical outcome with high HbA1c sug-
gests that screening patients and improving glycaemic control
before surgery may be beneficial. Although recommendations for
perioperative management of impaired glucose metabolism are
extrapolated largely from the critical care literature, general con-
sensus is that interventions in the acutely unwell or stressed
patient should be directed towards minimizing fluctuations in
blood glucose concentration whilst avoiding hypoglycaemia and
hyperglycaemia. In the ICU setting, insulin infusion should be
used to control hyperglycaemia, with the trigger for instigating
intravenous insulin therapy set at 10.0 mmol/L (180 mg/dL) and
relative trigger at 8.3 mmol/L (150 mg/dL). Although there is a
lack of agreement on target glucose range,targets below
6.1 mmol/L (110 mg/dL) are not recommended.240,241
Recommendations on blood glucose control
Recommendations Classa Levelb Ref. c
Post-operative prevention of 
hyperglycaemia [targeting levels at 
least <10.0 mmol/L (180 mg/dL)]
by intravenous insulin therapy is 
recommended in adults after high-
risk surgery that requires





In patients at high surgical risk, 
clinicians should consider 
screening for elevated HbA1c
before major surgery and 
improving pre-operative glucose 
control.
IIa C
Intra-operative prevention of 
hyperglycaemia with insulin may be 
considered.
IIb C
Post-operative targets <6.1 










Anaemia can contribute to myocardial ischaemia, particularly in
patients with CAD. In emergency surgery, transfusion may be
needed and should be given according to clinical needs. In elective
surgery, a symptom-guided approach is recommended as no scientif-
ic evidence is available to support other strategies.
7. Anaesthesia
The optimal perioperative course for high-risk cardiovascular
patients should be based on close co-operation between cardio-
logists, surgeons, pulmonologists, and anaesthesiologists. Pre-
operative risk assessment and pre-operative optimization of
cardiac disease should be performed as a team exercise. Guidelines
on pre-operative evaluation of the adult patient undergoing non-
cardiac surgery have previously been published by the European
Society of Anaesthesiology.244 The present edition focuses on
patients with cardiovascular risk factors and diseases and also takes
into account more recent developments, as well as perioperative
management of patients at increased cardiovascular risk.
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Most anaesthetic techniques reduce sympathetic tone, leading to a
decrease in venous return due to increased compliance of the
venous system, vasodilatation and, finally, decreased blood pressure;
thus, anaesthesiological management must ensure proper mainten-
ance of organ flow and perfusion pressure. Recent evidence suggests
that there is no universal ‘target blood pressure value’ to define
intra-operative arterial hypotension, but percentage decreases
.20% in mean arterial pressure, or mean arterial pressure values
,60 mmHg forcumulativedurationsof.30minutes, areassociated
with a statistically significant increase in the risk of post-operative
complications that include myocardial infarction, stroke, and
death.104,245,246 Similarly, increased duration (.30 minutes) of
deep anaesthesia (bispectral index scale values,45) was statistically
associated with an increased risk of post-operative complications.246
Efforts should be made to prevent intra-operative arterial hypoten-
sion and inadequately deep anaesthesia.
The choice of the anaesthetic agent has been considered to be of
little importance in terms of patient outcome, provided that vital func-
tions are adequately supported. There is conflicting evidence, stem-
ming from cardiac surgery, over whether a specific anaesthetic agent
is superior in patients with cardiac disease, with the suggestion that
volatile anaesthetic agents offer better cardioprotection than intraven-
ous agents. A meta-analysis published in 2013, combining standard and
Bayesian approaches on studies performed in adult cardiac surgery
patients, concluded that inhaled anaesthesia, as opposed to total intra-
venous anaesthesia, was associated with a 50% decrease in mortality
(from 2.6% in the total intravenous anaesthesia arm to 1.3% in the
inhaled anaesthetics arm); the Bayesian meta-analysis concluded that
mortalitywasthe lowest when sevofluranewasusedas the anaesthetic
agent.247 Comparable data relating to non-cardiac surgery are scarce.
One small study observed a lower incidence of major cardiac events in
vascular surgery patients anaesthetized with a volatile agent than with
an intravenous anaesthetic,248 but two other studies in non-cardiac
surgery patients observed no difference in outcome.249,250
However, the overall incidence of perioperative adverse events was
too low to be able to address the relationship between choice of an-
aesthetic agent and patient outcome.251
7.2 Neuraxial techniques
Spinal or epidural (globally known as neuraxial) anaesthesia also
induces sympathetic blockade. When reaching the thoracic derma-
tome level 4, a reduction in cardiac sympathetic drive may occur,
with subsequent reduction in myocardial contractility, heart rate,
and change in cardiac loading conditions. The benefit of neuraxial an-
aesthesia vs. general anaesthesia is much debated in the literature,
with proponents of a beneficial effect of neuraxial anaesthesia and
proponents of the lack of effect on criteria such as mortality or
severemorbidity (myocardial infarction, othercardiaccomplications,
pulmonary embolism, pulmonary complications, etc.). The same
debate applies to patients with CVDs who must undergo non-cardiac
surgery. Given the continuing debate on this subject we have esti-
mated that neuraxial anaesthesia and analgesia may be considered
for the management of patients with cardiovascular risk factors or
diseases.
One meta-analysis reported significantly improved survival and
reduced incidence of post-operative thrombo-embolic, cardiac,
and pulmonary complications using neuraxial blockade, compared
with general anaesthesia.252 An analysis of a large cohort of patients
undergoing colon resection also suggested improved survival with
epidural analgesia.253 Randomized studies and a meta-analysis of
several randomized clinical trials in non-cardiac surgery patients,
comparing outcomes with regional and general anaesthetic techni-
ques, have shown some evidence of improved outcome and
reduced post-operative morbidity with regional anesthesia.254 –256
A recent retrospective analysis, published in 2013, of nearly 400
000 patients undergoing total hip or knee arthroplasty, observed a
significantly lower incidence of major morbidity and mortality in
patients receiving neuraxial anaesthesia.257 The most recent
meta-analysis stated that, when epidurals or spinals were used to
replace general anaesthesia (but not when used to reduce the quan-
tity of drugs required to provide general anaesthesia), there was a sig-
nificant, 29% decrease in the risk of dying during surgery.10 In both
situations there was a significant decrease in the risk of pneumonia
(55% when replacing general anaesthesia and 30% when decreasing
the requirements of drugs used for general anaesthesia). In both
situations, neuraxial anaesthesia failed todecrease the riskof myocar-
dial infarction. In another recent meta-analysis that targeted patients
undergoing lower-limb revascularization (a category of patients with
risk factors for CVD), there was no difference in mortality, myocar-
dial infarction, or lower-limb amputation between patients allocated
to neuraxial anaesthesia vs. general anesthesia.258 Nevertheless,
neuraxial anaesthesia was associated with a significantly lower risk
of pneumonia.258 Both meta-analyses were based on relatively
small numbers of studies (with a high risk of bias) and patients, and
did not specifically target patients with documented cardiac
disease. Although there are no studies specifically analysing the
changes in outcome related to neuraxial anaesthetic techniques in
patients with cardiacdisease, the use of this technique may be consid-
ered in patients who do not have a contra-indication after estimation
of risk–benefit ratio. Cardiac patients are often on various types of
drugs that interfere with coagulation and care should be taken to
ensure sufficient coagulation ability when neuraxial blocks are
applied.259 Furthermore, combination of general anaesthesia with
thoracic epidural anaesthesia has been shown to statistically increase
the risk of arterial hypotension.260
7.3 Perioperative goal-directed therapy
There is accumulating evidence underlining the advantages of goal-
directed fluid therapy in non–cardiac-surgery patients. Goal-
directed therapy aims to optimize cardiovascular performance, in
order to achieve normal or even supranormal oxygen delivery to
tissues, by optimizing pre-load and inotropic function using prede-
fined haemodynamic targets. In contrast to clinical signs or arterial
pressure-orientated standard therapy, goal-directed therapy is
based on flow or fluid responsiveness of haemodynamic variables,
such as stroke volume, response to fluid challenges, stroke volume
or pulse pressure variation, or similar cardiac output optimization.
Although goal-directed therapy was initially based on the use of a pul-
monary artery catheter, less-invasive techniques have been devel-
oped, such as oesophageal Doppler and transpulmonary dilution
techniques, as well as advanced pressure waveform analysis. Early
ESC/ESA Guidelines2420





goal-directed fluid therapy—in the right patient cohort and with a
clearly defined protocol—has been shown to decrease post-
operative mortality and morbidity.261,262 The mortality benefit of
goal-directed fluid therapy was most pronounced in patients with
an extremely high risk of death (.20%). All high-risk patients under-
going major surgery had a benefit from goal-directed fluid therapy in
terms of complications.263 A meta-analysis published in 2014 demon-
strated that, in patients with CVDs, goal-directed therapy decreased
major morbidity without any increase in adverse cardiovascular
events.264
7.4 Risk stratification after surgery
Several recent studies have demonstrated that it is possible to stratify
the risk of post-operative complications and mortality with a simple
surgical ‘Apgar’ score.265 This post-event stratification might allow
redirecting patients to higher intensity units or selected post-
operative measurements of natriuretic peptides and troponin.3,266
7.5 Early diagnosis of post-operative
complications
Several recent publications have demonstrated that differences
between hospitals, in terms of post-operative mortality, are not due
to the incidence of complications but to the way in which they are
managed.267 These results suggest that early identification of post-
operative complications, allied to aggressive management, could de-
crease post-operative morbidity and mortality. Several recent
meta-analyses have demonstrated that increased post-operative
troponin and BNP concentrations after non-cardiac surgery were
associated with a significantly increased risk of mortality.55,266,268
The prospective Vascular Events In Noncardiac Surgery Patients
Cohort Evaluation (VISION) trial confirmed the results of these
meta-analyses.3 Taken together, theseresults indicate thatearly tropo-
nin measurement in selected patients could trigger therapeutic conse-
quences. A non-randomized trial demonstrated that a bundle of
interventions aimed at promoting homeostasis was associated with a
significantly decreased incidence of post-operative troponin elevation
and decreased morbidity.269 Pre-operatively and post-operatively,
patients whocouldmost benefit fromBNPorhigh-sensitivity troponin
measurements are those with METs ≤4 or with a revised cardiac risk
index value.1 for vascular surgery and.2 for non-vascular surgery.
Post-operatively, patients with a surgical Apgar score ,7 should also
be monitored with BNP or high-sensitivity troponin measurements, in
order to detect complications early, independently of their revised
cardiac risk index values.
7.6 Post-operative pain management
Severe post-operative pain, reported in 5–10% of patients, increases
sympathetic drive and delays recovery.270,271 Neuroaxial analgesia
with local anaesthetics, or opioids and/or alpha2-agonists, and intra-
venous opioids, alone or in combination with non-steroidal anti-
inflammatory drugs, seem to be the most effective regimens. The
benefit of invasive (neuraxial) analgesic techniques should be
weighed against potential dangers; this is especially important when
considering the use of neuraxial blockade in patients on chronic
antithrombotic therapy, due to the increased risk of developing a
neuraxial haematoma. A meta-analysis published in 2013, which
analysed the impact of epidural analgesia vs. systemic analgesia, con-
cluded that epidural analgesia was associated with a significant, 40%
decrease in mortality and a significant decrease in the risk of AF,
SVT, deep-vein thrombosis, respiratory depression, atelectasis,
pneumonia, ileus, and post-operative nausea and vomiting, and also
improved recovery of bowel function, but significantly increased
the risk of arterial hypotension, pruritus, urinary retention, and
motor blockade.272
The transition from acute, post-operative pain to chronic, post-
surgical pain is an unfortunate consequence of surgery that adversely
impacts the patient’s quality of life. The prevalence of chronic post-
surgical pain differs in various types of surgery. Limited data suggest
that local or regional analgesia, gabapentin or pregabaline, or intra-
venous lidocaine, might have a preventive effect against persistent
post-surgical pain and could be used in a high-risk population.273
Recommendations on anaesthesia
Recommendations Classa Levelb Ref. c
Patients with high cardiac and 
surgical risk should be 
considered for goal-directed 
therapy.
IIa B 261–264
The measurement of 
natriuretic peptides and high-
sensitivity troponin after 
surgery may be considered in 





Neuraxial anaesthesia (alone), 
in the absence of contra-
indications and after 
estimation of the risk–benefit 
ratio, reduces the risk of peri-
operative mortality and 
morbidity compared with 
general anaesthesia and may 
be considered.
IIb B 10,252–257
Avoiding arterial hypotension 
(mean arterial pressure <60 
mm Hg) for prolonged 
cumulative periods (>30 
minutes) may be considered.
IIb B 104,245,246
Neuraxial analgesia, in the 
absence of contra-indications, 




inflammatory drugs (especially 
cyclo-oxygenase-2 inhibitors) 
as the first-line analgesics in 
patients with IHD or stroke
may be considered. 
IIb B 279




Patient-controlled analgesia is an alternative for post-operative
pain relief. Meta-analyses of controlled, randomized trials have
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shown that patient-controlled analgesia has some advantages, with
regard to patient satisfaction, over nurse-controlled or on-demand
analgesia. No difference has been demonstrated with regard to mor-
bidity or final outcome. Patient-controlled analgesia is an adequate al-
ternative in patients not suited to regional anaesthesia. Routines for
follow-up and documentation of effects should be in place.270,274 – 276
Non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2
inhibitors have the potential for promoting heart and renal failure,
as well as thrombo-embolic events, and should be avoided in patients
with myocardial ischaemia or diffuse atherosclerosis. Recently, an
increased risk of cardiovascular events associated with diclofenac was
detected, specifically in a high-risk population.277 Cyclo-oxygenase-2
inhibitors cause less gastrointestinal ulceration and bronchospasm
than cyclo-oxygenase-1 inhibitors. The final value of these drugs in
the treatment of post-operative pain in cardiac patients undergoing
non-cardiac surgery has not been defined. These drugs should be
avoided in cases of renal and heart failure, or in patients who are
elderly, on diuretics, or those with unstable haemodynamics.278
8. Gaps in evidence
The Task Force has identified several major gaps in the available
evidence:
† There is lack of data on how non-cardiac risk factors (frailty,
extreme low or high body mass index, anaemia, immune status)
interact with cardiovascular risk factors and how they impact on
the outcomes of non-cardiac surgery.
† There is a need for risk scores that can predict mortality from non-
cardiac causes.
† Interventional oroutcome studies need tobeperformed, that take
into consideration increased pre-operative or post-operative
high-sensitivity troponin, BNP, and other biomarkers.
† Areas of uncertainty remain in terms of the optimal type, dose, and
duration of perioperative beta-blocker therapy in patients under-
going high-risk non-cardiac surgery.
† It remains unknown whether or not patients at intermediate sur-
gical risk derive benefit from perioperative beta-blocker therapy.
† Areas of uncertainty remain in terms of the potential benefit of the
introduction of statins in patients undergoing high-risk surgery.
† Interventional or outcome studies need to be performed on the
prevention or correction of haemodynamic abnormalities or
low bispectral index values that are statistically associated with
worse outcome.
† Information is lackingon the effects of patient status, operating team
size or skills, and the invasiveness of procedures, on outcomes fol-
lowing non-cardiac surgery and these will require investigations in
large, procedure-specific, randomized, multicentre studies.
9. Summary
Figure 3 presents, in algorithmic form, an evidence-based, stepwise
approach for determining which patients benefit from cardiac
testing, coronary artery revascularization, and cardiovascular
therapy before surgery. For each step, the Committee has included
the level of the recommendations and the strength of evidence in
the accompanying Table 8.
Step 1. The urgency of the surgical procedure should be assessed.
In urgent cases, patient- or surgery-specific factors dictate the strat-
egy and do not allow further cardiac testing or treatment. In these
cases, the consultant provides recommendations on perioperative
medical management, surveillance for cardiac events, and continu-
ation of chronic cardiovascular medical therapy.
Step 2. If the patient is unstable, this condition should be
clarified and treated appropriately before surgery. Examples are un-
stable coronary syndromes, decompensated heart failure, severe
arrhythmias, and symptomatic valvular disease. Stabilization usually
leads to cancellation or delay of the surgical procedure. For instance,
patients with unstable angina pectoris should be referred for coronary
angiography to assess the therapeutic options. Treatment options
should be discussed by a multidisciplinary expert team, including all
perioperative care physicians, because interventions might have
implications for anaesthesiological and surgical care. For example,
the initiation of dual anti-platelet therapy after coronary artery
stent placement might complicate locoregional anaesthesia or specif-
ic surgical procedures. Depending on the outcome of this discussion,
patients may either proceed for coronary artery intervention, namely
CABG, balloon angioplasty, or stent placement, with the initiation of
dual anti-platelet therapy if the index surgical procedure can be
delayed, or proceed directly for operation with optimal medical
therapy if delay is incompatible.
Step 3. In cardiac-stable patients, determine the risk of the surgical
procedure (Table 3). If the estimated 30-day cardiac risk of the pro-
cedure in cardiac stable patients is low (,1%), it is unlikely that
test results will influence management and it would be appropriate
to proceed with the planned surgical procedure. The physician can
identify risk factors and provide recommendations on lifestyle and
medical therapy to improve long-term outcome, as outlined in
Table 8. Initiation of a beta-blocker regimen may be considered
prior to surgery in patients with known IHD or myocardial ischaemia.
Treatment should ideally be initiatedbetween30days andaminimum
of 2 days before surgery and should be continued post-operatively.
Beta-blockade should be started with a low dose, slowly up-titrated
and tailored to achieve a resting heart rate of between 60 and 70 bpm
with systolic blood pressure .100 mm Hg. In patients with heart
failure and systolic LV dysfunction, indicated by LVEF ,40%, ACEIs
(or ARBs in patients intolerant of ACEIs) should be considered
before surgery. In patients undergoing vascular surgery, initiation of
statin therapy should be considered. Discontinuation of aspirin
should be considered in those patients in whom haemostasis is diffi-
cult to control during surgery.
Step 4. Consider the functional capacity of the patient. If an asymp-
tomatic or cardiac-stable patient has moderate or good functional
capacity (.4 METs), perioperative management is unlikely to be
changed on the basis of test results, irrespective of the planned sur-
gical procedure. Even in the presence of clinical risk factors, it is ap-
propriate to refer the patient for surgery. The recommendations
for medication are the same as in Step 3.
Step 5. In patients with a moderate or poor functional capacity,
consider the risk of the surgical procedure, as outlined in Table 3.
Patients scheduled for intermediate-risk surgery can proceed for
surgery. In addition to the suggestions above, in patients with one
or more clinical risk factors (Table 4), a pre-operative baseline ECG
is recommended to monitor changes during the surgical procedure.
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Step 1 Urgent surgery
Patient or surgical specific factors dictate the strategy, and do not allow further 
cardiac testing or treatment. The consultant provides recommendations on 
peri-operative medical management, surveillance for cardiac events and 
continuation of chronic cardiovascular medical therapy.
No
Yes
Step 2 One of active or unstable
cardiac conditions (table 9)
Treatment options should be discussed in a multidisciplinary team, involving all 
peri-operative care physicians as interventions might have implication on 
anaesthesiological and surgical care. For instance in the presence of unstable 
angina, depending on the outcome of this discussion, patients can proceed for 
coronary artery intervention, with the initiation of dual-anti platelet therapy if 
the index surgical procedure can be delayed, or directly for operation if delay 
is impossible with optimal medical therapy. 
No
Yes
Step 3 Determine the risk of the
surgical procedure (table 3)
The consultant can identify risk factors and provide recommendations on 
lifestyle and medical therapy, according to the ESC Guidelines.
In patients with one or more clinical risk factors, preoperative baseline 
ECG may be considered to monitor changes during the peri-operative 
period.
In patients with known IHD or myocardial ischaemia, initiation of a titrated 
low-dose beta-blocker regimen may be considered before surgerya.
In patients with heart failure and systolic dysfunction, ACEI should be 
considered before surgery.




Step 4 Consider the functional 
capacity of the patient
< 4 METs
> 4 METs
Step 5 In patients with a poor functional capacity
consider the risk of the surgical procedure  
In addition to suggestions above:






Step 6 Cardiac risk factors (table 4)
In addition to suggestions above:
Rest echocardiography and biomarkers may be considered for evaluation of LV 





Consider non-invasive testing. Non-
invasive testing can also be considered
prior to any surgical procedure for patient
counselling, change of peri-operative
management in relation to type of
surgery and anaesthesia technique. 
Balloon angioplasty: 
Surgery can be performed 
> 2 weeks after intervention 
with continuation 
of aspirin treatment. 
Bare-metal stent:
Surgery can be performed 
>4 weeks after intervention. 
Dual antiplatelet therapy 
should be continued for 
at least 4 weeks.
Surgery can be performed
within 12 months after 
intervention for old-generation 
DES and within 6 months for 
new-generation DES.
Continuation or discontinuation of aspirin in patients previously treated
with aspirin may be considered in the peri-operative period, and should be
based on an individual decision that depends on the peri-operative bleeding
risk weighed against the risk of thrombotic complications (see also Table 8).
CABG
Interpretation of non-invasive
stress test results 
Surgery
Proceed with the planned surgeryb. 
An individualized peri-operative management is recommended considering 
the potential benefit of the proposed surgical procedure compared with the 









aTreatment should be initiated optimally between 30 days and at least 2 days before surgery and should be continued postoperatively aiming at target resting heart rate of 60–70
beats per minute and systolic blood pressure >100 mmHg. 
bFor strategy of anaesthesia and perioperative monitoring see appropriate sections.
ACEI = angiotensin converting enzyme inhibitor; CABG = coronary artery bypass graft; DES = drug-eluting stent ECG = electrocardiogram; IHD = ischaemic heart disease;
MET =  metabolic equivalent.
Figure 3 Summary of pre-operative cardiac risk evaluation and perioperative management.
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Step 6. In patients scheduled for high-risk surgery, consider
non-invasive testing in patients with more than two clinical risk
factors (Table 4). Non-invasive testing can also be considered
before any surgical procedure for patient counselling, or change of
perioperative management in relation to type of surgery and anaes-
thesia technique. Risk factors can be identified and medical therapy
optimized as in Step 3.
Step 7. Interpretation of non-invasive stress test results:
patients without stress-induced ischaemia—or with mild-to-
moderate ischaemia suggestive of one- or two-vessel disease—can
proceed to the planned surgical procedure. In patients with extensive
stress-induced ischaemia (as assessed by non-invasive testing),
individualized perioperative management is recommended,
taking into consideration the potential benefit of the proposed
surgical procedure, weighed against the predicted adverse
outcome. Also, the effect of medical therapy and/or coronary
revascularization must be assessed, not only for immediate post-
operative outcome, but also for long-term follow-up. In
patients referred for percutaneous coronary artery intervention,
the initiation and duration of anti-platelet therapy will
interfere with the planned surgical procedure (see sections 4.2
and 4.4).
Table 8 Summary of pre-operative cardiac risk evaluation and peri-operative management
ACE ¼ angiotensin converting enzyme; BNP ¼ brain natriuretic peptide; ECG ¼ electrocardiogram; IHD ¼ ischaemic heart disease; LV ¼ left ventricular. Hatched areas: treatment
options should be considered by a multidisciplinary Expert Team.
aType of surgery (Table 3): risk of myocardial infarction and cardiac death within 30 days of surgery.
bClinical risk factors presented in Table 4.
cIn patients without signs and symptoms of cardiac disease or ECG abnormalities.
dNon-invasive testing, not only for revascularization, but also for patient counselling, change of peri-operative management in relation to type of surgery, and anaesthesia technique.
eInitiation of medical therapy, but in the case of emergency surgery, continuation of current medical therapy.
fTreatment should be initiated ideally less than 30 days and at least 2 days before surgery and should be continued post-operatively, aiming at a target heart rate of 60–70 beats per
minute and systolic blood pressure .100 mm Hg.
gUnstable cardiac conditions presented in Table 9. Recommendations are based on current guidelines, recommending assessment of LV function and ECG in these conditions.
hIn the presence of heart failure and systolic LV dysfunction (treatment should be initiated at least 1 week before surgery).
iIn patients with known IHD or myocardial ischaemia.
jIn patients undergoing vascular surgery.
kEvaluation of LV function with echocardiography and assessment of BNP are recommended in patients with established or suspected HF before intermediate- or high-risk surgery in
patients with established or suspected HF (I A).
lIn the presence of American Society of Anesthesiologists class ≥3 or revised cardiac risk index ≥2.
mAspirin should be continued after stent implantation (for 4 weeks after BMS and 3–12 months after DES implantation).
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ESC National Cardiac Societies actively involved in the
review process of the 2014 ESC/ESA Guidelines on
non-cardiac surgery: cardiovascular assessment and
management
Austria, Austrian Society of Cardiology, Bernhard Metzler –
Azerbaijan, Azerbaijan Society of Cardiology, Rahima Gabulova
– Belarus, BelorussianScientific Societyof Cardiologists,Alena Kur-
lianskaya – Belgium, Belgian Society of Cardiology, Marc J Claeys –
Bosnia and Herzegovina, Association of Cardiologists of Bosnia &
Herzegovina, Ibrahim Terzic´ – Bulgaria, Bulgarian Society of Cardi-
ology, Assen Goudev – Cyprus, Cyprus Society of Cardiology,
Petros Agathangelou – Czech Republic, Czech Society of Cardi-
ology, Hana Skalicka – Denmark, Danish Society of Cardiology,
Lone Due Vestergaard – Estonia, Estonian Society of Cardiology,
Margus Viigimaa – Finland, Finnish Cardiac Society, Kai Lindgren
– France, French Society of Cardiology, Ge´rald Vanzetto –
Georgia, Georgian Society of Cardiology, Zurab Pagava –
Germany, German Cardiac Society, Malte Kelm – Greece, Hellen-
ic Cardiological Society, Costas Thomopoulos – Hungary, Hungar-
ian Society of Cardiology, Robert Gabor Kiss – Iceland, Icelandic
Society of Cardiology, Karl Andersen – Israel, Israel Heart
Society, Zvi Vered – Italy, Italian Federation of Cardiology, Fran-
cesco Romeo – Kyrgyzstan, Kyrgyz Society of Cardiology, Erkin
Mirrakhimov – Latvia, Latvian Society of Cardiology, Gustavs Lat-
kovskis – Lebanon, Lebanese Society of Cardiology, Georges
Saade – Libya, Libyan Cardiac Society, Hisham A. Ben Lamin –
Lithuania, Lithuanian Society of Cardiology, Germanas Marinskis
– Malta, Maltese Cardiac Society, Mark Sammut – Poland, Polish
Cardiac Society, Janina Stepinska – Portugal, Portuguese Society of
Cardiology, Joa˜o Manuel Pereira Coutinho – Romania, Romanian
Society of Cardiology, Ioan Mircea Coman – Russia, Russian
Society of Cardiology, Dmitry Duplyakov – Serbia, Cardiology
Society of Serbia, Marina Deljanin Ilic – Slovakia, Slovak Society of
Cardiology, Juraj Du´brava – Spain, Spanish Society of Cardiology,
Vicente Bertomeu – Sweden, Swedish Society of Cardiology, Chris-
tina Christersson – The Former Yugoslav Republic of
Macedonia, Macedonian FYR Society of Cardiology, Marija Vavlukis
– Tunisia, Tunisian Society of Cardiology and Cardio-Vascular
Surgery, Abdallah Mahdhaoui – Turkey, Turkish Society of Cardi-
ology, Dilek Ural – Ukraine, Ukrainian Association of Cardiology,
Alexander Parkhomenko – United Kingdom, British Cardiovascu-
lar Society, Andrew Archbold.
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